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ABSTRACT 
Previous research suggests that intranasal oxytocin may promote trust, social 
cooperation, in-group favoritism, and empathic concern in humans. Oxytocin therefore 
has therapeutic implications for psychological disorders such as social anxiety disorder 
(SAD). In particular, oxytocin may have anxiety-buffering effects in the context of social 
rejection. Oxytocin may promote cooperative social behavior with other individuals 
despite being rejected by them, as research has shown that oxytocin facilitates decisions 
indicative of sustained trust even despite breaches of trust. Using a double-blind, placebo-
controlled design, the current investigation examined whether oxytocin modulates 
responses to social rejection from an initially cooperative confederate, and whether it 
modulates attentional processes toward social stimuli (disgust, neutral, and happy face 
stimuli). Participants were 54 individuals with SAD, who were randomly assigned to 
receive 24 international units (IU) of oxytocin or placebo nasal spray. Following drug 
administration, participants completed a computerized ball-tossing game called 
Cyberball, in which they were led to believe that they were playing “on-line” with three 
other fictitious players. The amount of reciprocation displayed by other players was 
vi 
manipulated, such that Player 1 was programmed to play cooperatively during the first 
half of the game (tossed 70% of his balls to the participant), and then switched to less 
cooperative play during the second half (tossed 10% of balls to the participant). After 
Cyberball, participants completed a modified version of the Posner Task. Results showed 
that oxytocin improved cooperation with Player 1 in the second half of the game, but only 
for individuals with low attachment avoidance. Oxytocin also amplified subjective 
ratings of perceived rejection by others during Cyberball for individuals with high 
rejection sensitivity. Furthermore, oxytocin led to facilitated disengagement from all 
social cues regardless of emotional valence and speeded up detection of disgust and 
neutral faces, compared to placebo, but only for individuals with high attachment 
avoidance. These findings suggest that oxytocin may promote social cooperation, as well 
as a flexible attentional pattern toward social cues, at least for some individuals with 
SAD. Future research should address individual differences in responses to oxytocin, and 
further investigate the comparative effects of oxytocin in healthy individuals.  
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Introduction 
First described by the British physiologist Sir Henry Hallett Dale in 1906, 
oxytocin is a nine amino acid neuropeptide, which is produced in the paraventricular and 
supraoptic nuclei of the hypothalamus. It is then secreted via the posterior pituitary gland 
into peripheral circulation or released into the central nervous system to act on receptors 
widely distributed throughout the brain in the limbic system, midbrain, and brainstem. Sir 
Henry Hallett Dale coined the name oxytocin from the Greek words meaning “swift 
birth,” due to his observations that extracts from the human posterior pituitary gland 
contracted the uterus of a pregnant cat. In 1953, oxytocin was sequenced and synthesized 
by Vincent du Vigneaud, making it the first peptide hormone to be synthesized. Today, 
synthetic oxytocin (marketed as Pitocin® and Syntocinon®) is commonly administered 
intravenously to induce or augment labor in pregnant women.   
Traditionally, oxytocin has been examined for its role in childbirth, lactation, and 
maternal attachment. Following recent advances in translational neuroscience to deliver 
oxytocin directly to the central nervous system, studies have revealed that oxytocin has 
much broader functions in social cognition and behavior than previously thought. Animal 
studies have shown that central administration of oxytocin to pairs of rats increases the 
duration of physical contact with each other (Witt, Winslow, & Insel, 1992), whereas 
administration of an oxytocin receptor antagonist in male rats is associated with reduced 
social exploration of a con-specific male rat (Lukas et al., 2011). Similarly, male 
knockout mice who lack oxytocin receptors in the forebrain do not discriminate between 
familiar and novel females, and spend significantly less time investigating new females 
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they have met for the first time, compared to normal mice (Macbeth, Lee, Edds, & 
Young, 2009).  
In humans, intranasal delivery of oxytocin appears to promote pro-social 
behaviors such as in-group favoritism (De Dreu, Greer, Van Kleef, Shalvi, & Handgraaf, 
2011), trust and cooperation (De Dreu, 2012b; Kosfeld, Heinrichs, Zak, Fischbacher, & 
Fehr, 2005), empathy (Hurlemann et al., 2010), and emotion recognition (Schulze et al., 
2011). Intranasal oxytocin also appears to have anxiolytic properties, as it buffers 
responses to social stress (Heinrichs, Baumgartner, Kirschbaum, & Ehlert, 2003), 
dampens amygdala activity to emotional stimuli (Domes et al., 2007), and reduces 
cortisol levels during couple conflict (Ditzen et al., 2009). However, recent research has 
shed light on the context-dependent and divergent effects of oxytocin, and suggests that 
its effects may depend on certain individual difference factors such as sex, hormonal 
status, attachment orientation, and psychiatric status (for a review, see MacDonald, 
2013). Such research indicates that under certain conditions, oxytocin may even exert 
anxiogenic effects. Evidence from studies examining the effect of intranasal oxytocin in 
various clinical populations also reflects this mixed picture (Bartz et al., 2011). 
Nevertheless, intranasal oxytocin is a promising agent and has major treatment 
implications for psychiatric disorders involving deficits in social functioning such as 
autism, schizophrenia, borderline personality disorder, and social anxiety disorder. In 
particular, oxytocin may represent a candidate endophenotype for social anxiety disorder, 
as it may serve as a biological indicator associated with stable behavioral phenotypes that 
confer risk for social anxiety disorder (e.g., behavioral inhibition, abnormalities in 
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information processing such as attentional biases to social threat information). Oxytocin 
may also serve as a cognitive enhancer for psychological treatments (e.g., cognitive-
behavioral therapy) that rely on specific learning processes, such as fear extinction and 
memory consolidation. Further research is needed to better understand oxytocin’s 
mechanisms of action and the conditions under which it demonstrates beneficial effects.   
Toward this end, the current project aimed to investigate the pro-social effects of 
oxytocin in individuals with social anxiety disorder, particularly in the context of social 
rejection and attentional processing of social stimuli. Intranasal oxytocin has the potential 
of serving as a novel treatment strategy for social anxiety disorder. The current research 
reflects an innovative translational approach to examining core patterns of 
psychopathology underlying social anxiety disorder, which may inform potential 
mediators of symptom severity, and thereby ultimately elucidate mechanisms to target in 
treatment intervention. Given recent research highlighting the benefits of 
psychopharmacological agents in facilitating change in psychopathology (Hofmann, 
Smits, Asnaani, Gutner, & Otto, 2011; Meyer-Lindenberg, Domes, Kirsch, & Heinrichs, 
2011), this project aimed to significantly advance knowledge regarding the proposed 
benefit of a promising agent. 
 
Oxytocin Studies in Healthy Samples 
Effects on pro-social behavior. A seminal study by Kosfeld and colleagues (2005) 
examined the effect of a single administration of 24 international units (IU) of an 
oxytocin nasal spray (or placebo) on monetary transfers in a social trust game and a non-
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social risk game. The sample consisted of 194 healthy adult males (mean age = 22 years), 
who had no medical or psychiatric illnesses and were medication-free. Participants were 
randomly assigned the role of “Investors” or “Trustees.” During the trust game, Investors 
were given an initial endowment of 12 monetary units, and were then asked to provide a 
transfer to a Trustee in the amount of 0, 4, 8, or 12 monetary units, which the 
experimenter tripled. The Trustee was then asked to provide a back transfer amount 
ranging between 0 to 48 monetary units. Investors who were given oxytocin transferred 
significantly more money to Trustees, compared to Investors who were given placebo, 
despite the risk of Trustees not returning any proceeds of the transfer. During a risk game 
that served as a non-social control condition, which involved a random mechanism to 
generate back transfer amounts to the Investor, there was no effect of oxytocin. This 
suggests that oxytocin’s effects may be specific to social interactions.  
While the results of this study provided compelling evidence for the “pro-trust” 
effects of oxytocin, they highlighted several methodological issues germane to the study 
as well as the oxytocin literature more broadly. Aside from the question of whether 
results would generalize to women, older adults, children, or those with psychiatric 
illnesses, one major issue is the ecological validity of the experimental paradigm, and 
whether it captures the motivational aspects underlying real social interactions. For 
example, these results may not be generalizable to social interactions involving familiar 
others, where giving low back transfer amounts may impact future interactions. 
Participants were relatively anonymous in the study, which is often atypical of human 
interactions. In addition, more social information is typically present in real face-to-face 
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interactions, which may impact norms to reciprocate. Therefore, further research is 
needed to elucidate for whom and under what social contexts oxytocin’s pro-social 
effects may apply.  
Indeed, several studies have replicated oxytocin’s effects on trust and cooperation 
in healthy samples (De Dreu, Greer, Handgraaf, Shalvi, & Van Kleef, 2012; Klackl, 
Pfundmair, Agroskin, & Jonas, 2013; Mikolajczak et al., 2010). One meta-analysis (Van 
Ijzendoorn & Bakermans-Kranenburg, 2012) reported that oxytocin’s effects may depend 
on in-group and out-group categorization, as oxytocin may elevate levels of in-group 
trust, but may not impact out-group trust. The combined effect size for in-group trust was 
moderate and significant (d = 0.48), whereas the combined effect size for out-group trust 
was not significant. These findings provided support for the moderating impact of in-
group or out-group status on oxytocin’s effects; however, this meta-analysis was subject 
to the same methodological issues of the individual studies that comprised it, such as 
biased samples (largely inclusive of adult males), different dose amounts, and varied 
designs and task demands. These discrepancies significantly limited the interpretability of 
the results and prohibited moderator analyses, which sought to examine the impact of sex 
and type of placebo used.   
Effects on social cognition. Studies examining the effects of intranasal oxytocin 
on social cognition largely comprise two broad categories: facial recognition of 
emotional expressions and attentional orienting toward social information. The same 
meta-analysis described above (Van Ijzendoorn & Bakermans-Kranenburg, 2012) 
reported combined effects of oxytocin on emotion recognition and found a significant, 
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but weak, effect (d = 0.21). This is consistent with a more recent meta-analysis, which 
showed that intranasal oxytocin improved emotion recognition, with a combined Hedges’ 
g = 0.29 (Shahrestani, Kemp, & Guastella, 2013). Using similar inclusion criteria, this 
meta-analysis included seven randomized controlled trials of intranasal oxytocin with 
placebo controls, healthy participants (no clinical samples), and only full-face images of 
basic emotions from validated stimulus sets. All studies used either the 24 IU or 40 IU 
dose of oxytocin. Oxytocin facilitated the accurate recognition of all basic emotions. It 
was more beneficial for recognizing anger, happiness, and combined emotions at the 
automatic, implicit level, and more beneficial for recognizing fear at the explicit, 
controlled processing level. These findings suggest that a single administration of 
oxytocin may facilitate the accurate identification of basic human emotions at both 
automatic and effortful stages of processing. However, the mechanisms underlying this 
effect remain unclear. Some proposed mechanisms may be an increased salience of social 
cues (Prehn et al., 2013), increased pupil dilation (Leknes et al., 2012), or faster orienting 
toward social cues (Ellenbogen, Linnen, Grumet, Cardoso, & Joober, 2012).  
A related aspect of social cognition that has been investigated is whether oxytocin 
facilitates attentional orienting of social and emotional information (for a review, see 
Guastella & MacLeod, 2012). Typically, these studies assess the effect of a single 
administration of oxytocin or placebo on attentional engagement and disengagement from 
emotional faces by measuring response times to categorize neutral target stimuli, which 
appear in congruent and incongruent locations as a visual probe. For example, one study 
examined the effect of intranasal oxytocin on attention shifting to emotional faces using 
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this type of spatial cueing paradigm (Ellenbogen et al., 2012). Fifty-seven participants 
(30 females, ages 18-35), who were without any medical or psychiatric illnesses, without 
sensory impairments, and were non-smokers and non-drug users, took part in the study. 
After receiving a nasal spray containing either 24 IU of oxytocin or placebo, participants 
were instructed to respond as quickly as possible when a target stimulus (black dot) 
appeared in the left or right side of the computer screen. Prior to each target presentation, 
a cue appeared on either side of the screen, consisting of a picture of a sad, angry, or 
neutral face (either male or female), which were taken from a validated facial stimulus set 
(Ekman & Friesen, 1976). A unique aspect of this study was the use of short (17 ms) and 
long (250 and 750 ms) stimulus exposure latencies to examine the differential impact of 
oxytocin on automatic and effortful processing.  
Investigators found that oxytocin attenuated engagement toward sad faces and 
facilitated disengagement from sad and angry faces during effortful processing, but did 
not attenuate engagement toward emotional faces during automatic processing. 
Interestingly, depression levels significantly moderated oxytocin’s effects during 
automatic processing, as oxytocin appeared to normalize disengagement patterns for 
masked angry faces for those with high depression scores. Sex was found to have no 
significant main or interaction effects.  
While these results may not be extrapolated to clinically depressed individuals, 
they are consistent with previous findings showing that oxytocin enhances the processing 
of social information, regardless of emotional valence (Gamer, Zurowski, & Büchel, 
2010). Where these findings depart from previous studies of attention is that some studies 
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have found effects of oxytocin specifically on early stages of attention processing 
(Domes, Sibold, et al., 2013). One explanation for these disparate findings is that studies 
have employed various study designs, emotional stimuli, and tasks. Nevertheless, these 
studies reflect a common theme, that oxytocin impacts social information processing by 
moderating attentional mechanisms. Future research should examine whether oxytocin 
impacts other cognitive processes, such as memory consolidation or fear learning, as 
initial research in this area has already begun. For example, researchers discovered that 
oxytocin impairs extinction training in rats and mice when given prior to extinction 
training, which suggests that the effects of oxytocin on fear learning may depend on the 
timing of administration (Toth, Neumann, & Slattery, 2012).  
Anxiolytic and anxiogenic effects. Oxytocin’s anxiolytic effects have been well-
documented in several studies (Bakermans-Kranenburg & Van Ijzendoorn, 2013; Domes 
et al., 2007; Heinrichs et al., 2003). For example, oxytocin reduces cortisol levels in 
response to physical stress in a dose-dependent manner (Cardoso, Ellenbogen, Orlando, 
Bacon, & Joober, 2013), and modulates social fear-related neural circuitry by dampening 
amygdala reactivity to emotional faces regardless of valence (Domes et al., 2007). 
Studies also show that oxytocin’s anxiolytic effects are more pronounced in the context 
of social stimuli (e.g., faces compared to non-social scenes) (Kirsch et al., 2005). 
Furthermore, one study examining the effect of oxytocin on responses to a social stress 
task found that oxytocin had an enhanced buffering effect in the presence of social 
support (Heinrichs et al., 2003). Subjects were 37 healthy men (mean age = 23.8 years) 
devoid of chronic diseases, mental disorders, medication, smoking, and drug or alcohol 
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abuse. They were instructed to attend the experiment either with their best friend (male or 
female) or alone, and that support providers were to be as helpful as possible during the 
10-minute preparation period for the task called the Trier Social Stress Test. After being 
randomly assigned to receive a 24 IU dose of oxytocin or placebo, participants were 
introduced to the speech task, in which they were asked to give a 5-minute public 
speaking task for a job interview, and to perform a 5-minute mental arithmetic task out 
loud. Salivary cortisol levels were also measured at eight time periods before and after 
the stress period.  
Researchers found that those receiving either social support or oxytocin, or both, 
showed increasing subjective feelings of calmness and decreasing anxiety during the 
stress task. In addition, the lowest cortisol concentrations during stress were found for 
subjects who received both oxytocin and social support. These findings suggest that 
oxytocin enhances the protective properties of social support during psychosocial stress. 
Given that those subjects who received both social support and oxytocin showed the 
strongest anxiolytic effects, these findings generate a new hypothesis that a dysregulated 
oxytocin system may impair or lessen the stress-buffering effect of social support, 
particularly in those with psychological disorders involving deficits in social functioning.  
Results from this study contrast with contradictory findings showing anxiogenic 
effects of oxytocin in healthy adults. For example, one study found that oxytocin 
increased anxiety in response to unpredictable threat (Grillon et al., 2013). Subjects (43 
healthy men and women) received oxytocin, placebo, and a related neuropeptide, 
vasopressin, on three separate sessions, and completed a startle paradigm involving 
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predictable and unpredictable shocks. Defensive responses, as measured by startle 
response magnitude, were significantly increased by oxytocin, compared to the other 
drug conditions, and only in response to unpredictable shocks. The authors concluded 
that these anxiogenic effects may explain why oxytocin impacts responses to in-group 
and out-group members differently, as out-group members may be perceived as more 
unpredictable. However, the generalization of these findings to the social domain may be 
questionable, given that the paradigm used in this study may not reflect the complex 
emotional, biological, and psychological processes inherent to social interactions. Rather, 
what it may show is that oxytocin can have anxiogenic effects, particularly under 
conditions of uncertainty. Further research is needed to elucidate these mixed findings 
showing both anxiolytic and anxiogenic effects of oxytocin, perhaps by exploring the 
moderating effects of individual difference factors and employing within-group designs.  
 
Oxytocin Studies in Clinical Samples 
 Effect on pro-social behavior and social cognition. The available literature on 
oxytocin in clinical samples is relatively lacking, and reflects the mixed findings that 
have been found in healthy samples. On the one hand, evidence has shown that oxytocin 
may normalize dysfunctional social cognitive processes in individuals with high-
functioning autism (Andari et al., 2010), schizophrenia (Averbeck, Bobin, Evans, & 
Shergill, 2011), and social anxiety disorder (Labuschagne et al., 2010). In contrast, 
studies have found no effects of oxytocin on emotion recognition (Davis et al., 2013), as 
well as hindering effects of oxytocin (Bartz et al., 2011; MacDonald et al., 2013), in 
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clinical populations. As in the healthy human literature, methodological differences in 
study design, dose amount, dose frequency, and timing of oxytocin administration may 
explain these contradictory findings. In addition, an emerging line of research suggests 
that mixed findings can be partially attributed to individual difference factors, such as 
sex, hormonal status, attachment orientation, and psychiatric status, which have not been 
systematically measured or controlled in previous studies.   
An influential study by Bartz and colleagues (2011) tested the hypothesis that 
intranasal oxytocin may not universally improve trust and cooperative behavior. The 
investigators examined the comparative effects of oxytocin in 14 individuals with 
borderline personality disorder (BPD) and 13 healthy adults (mean age = 35 years). 
Healthy controls had no Axis I or II psychiatric comorbidities, and individuals with BPD 
were excluded if they had any current substance use disorders, major depression, eating 
disorders, schizophrenia, bipolar, or mental retardation. Subjects were not taking 
psychotropic or other medications for at least two weeks before the study began (five 
weeks for fluoxetine). After being randomly assigned to receive an oxytocin (40 IU) or 
placebo nasal spray, subjects were briefly introduced to a partner (confederate) for the 
Assurance Game, which is a variation of the Prisoner’s Dilemma. In this variation, the 
highest payoff ($6) for both players occurs when they mutually cooperate. If both players 
defect, they each would win $2, and if only one player defects, that individual would win 
$4 and the other would win $0. Researchers found that BPD participants expected their 
partners to be significantly less cooperative after receiving oxytocin, compared to 
placebo, and were more likely to defect during a hypothetical scenario in which their 
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partner cooperated. In contrast, healthy participants showed reverse effects in which 
oxytocin facilitated trust. Effects of age or sex were not reported in this study.  
When collapsing across diagnostic categories, further analyses revealed that these 
outcomes were moderated by attachment orientation, as oxytocin resulted in less trusting 
expectations for anxiously attached participants, but had no effect for those who were low 
in anxious attachment. Interestingly, oxytocin enhanced actual cooperation for high 
anxious/low avoidant participants, but decreased cooperation for high anxious/high 
avoidant participants. Whereas attachment anxiety refers to anxiety about rejection and 
abandonment by others, attachment avoidance refers to discomfort with closeness and 
intimacy (Brennan, Clark, & Shaver, 1998). These findings are consistent with another 
study documenting oxytocin’s anxiogenic effects in patients with major depressive 
disorder, especially in contexts involving an unfamiliar other, which suggest that the 
presence of psychiatric illness may moderate the divergent effects of oxytocin 
(MacDonald et al., 2013).  
Effect on psychiatric symptoms. A recent meta-analysis (Bakermans-Kranenburg 
& Van Ijzendoorn, 2013) examining the effect of intranasal oxytocin across various 
clinical populations, including autism, social anxiety, depression, obsessive-compulsive 
disorder, schizophrenia, borderline personality disorder, and posttraumatic stress 
disorder, found a small to moderate effect size (d = .32) on psychiatric symptomatology 
and social competence indicators. However, the results should be interpreted cautiously, 
given the heterogeneity of the samples, dose amounts, and dose frequencies included in 
the study. For example, it remains unclear how acute versus chronic administration of 
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intranasal oxytocin affects psychiatric outcomes. Available studies show mixed evidence 
for chronic administrations of oxytocin, even within the same disorder (Dadds, 
MacDonald, et al., 2013; Tachibana et al., 2013).   
 
Oxytocin and Social Anxiety Disorder   
Although the application of oxytocin is particularly amenable to the study of 
social anxiety disorder (SAD), this area of research is still in its nascent stages and is 
extremely limited. SAD is a highly distressing psychological disorder that is 
characterized by a persistent fear of negative evaluation by others in social or 
performance situations (American Psychiatric Association, 2013). With a lifetime 
prevalence of 12.1% (Kessler, Chiu, Demler, Merikangas, & Walters, 2005), SAD is the 
most common anxiety disorder in the U.S., and is associated with significant impairment 
in occupational, academic, and interpersonal functioning (Hofmann & Otto, 2008; Ruscio 
et al., 2008). Existing psychological treatments for SAD are efficacious, particularly 
cognitive-behavioral therapy; however, evidence suggests that there is still room for 
improvement, as approximately 50% of patients still remain symptomatic following CBT 
with or without medication treatment (Davidson et al., 2004; Hofmann & Smits, 2008).  
The available literature on the use of intranasal oxytocin in SAD patients has 
provided some insight into potential mechanisms underlying oxytocin’s behavioral 
effects in this patient population. To date, only three studies have been conducted 
applying intranasal oxytocin in SAD patients (Guastella, Howard, Dadds, Mitchell, & 
Carson, 2009; Labuschagne et al., 2010; Labuschagne et al., 2011), and two additional 
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studies have measured plasma oxytocin levels in patients with SAD (Hoge, Pollack, 
Kaufman, Zak, & Simon, 2008; Hoge et al., 2012). It appears that greater symptom 
severity of SAD may actually be associated with greater endogenous levels of plasma 
oxytocin, as oxytocin may be produced in greater quantities to compensate for 
dysfunctional oxytocin receptors in patients with social deficits (Hoge et al., 2008). This 
suggests that SAD patients may have abnormal plasma oxytocin levels compared to 
healthy individuals (Hoge et al., 2008). Furthermore, recent evidence suggests the 
presence of an altered pattern of oxytocin levels in patients with SAD, as they were found 
to have lower levels of plasma oxytocin after a Trust Game, compared to healthy 
controls, after controlling for sex and estradiol levels (Hoge et al., 2012). It remains 
unclear how intranasal versus systemic administration of neuropeptides differentially 
impacts uptake in the cerebrospinal fluid (CSF) and bloodstream, although some 
evidence suggests that intranasal delivery of neuropeptides may occur without uptake 
into the blood (Born et al., 2002). Nevertheless, studies examining plasma oxytocin may 
provide relatively weak evidence for the role of oxytocin in SAD, as peripheral levels of 
oxytocin may not be correlated with central release (Meyer-Lindenberg et al., 2011).  
Among studies that have administered intranasal oxytocin to SAD patients, one 
study examined the effect of administering oxytocin as an adjunct to exposure therapy for 
SAD and found that patients treated with oxytocin showed greater improvements in their 
ratings of speech performance and speech appearance, compared to patients treated with 
placebo, although there were no differences between groups on SAD symptom outcomes 
following treatment (Guastella et al., 2009). Another study demonstrated that intranasal 
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oxytocin attenuated amygdala reactivity to fearful faces in patients with generalized SAD 
using an emotional face matching paradigm with fearful, angry, and happy faces 
(Labuschagne et al., 2010). A more recent finding from the same research group showed 
that intranasal oxytocin attenuated cortical hyperactivity in the medial prefrontal cortex to 
sad faces (a non-threatening negative social cue) in patients with generalized SAD to a 
level similar to that of controls (Labuschagne et al., 2011). Taken together, these studies 
are consistent with previous research in healthy individuals showing pro-social effects of 
oxytocin in humans, and suggest that oxytocin’s dampening effects on fear-related neural 
circuitry may potentially mediate treatment outcomes for SAD patients.  
More specific to the current study, oxytocin’s perceptual and behavioral effects 
have direct implications for buffering responses to social rejection and reducing the fear 
of or sensitivity to social rejection in SAD patients. Indeed, the fear of social rejection 
represents a core construct involved in the psychopathology of SAD. Cognitive models of 
SAD propose that the fear of social rejection is associated with cognitive biases, such as 
hypervigilance to social threat and a tendency to interpret and anticipate rejection from 
others (Clark & Wells, 1995; Hofmann, 2007; Rapee & Heimberg, 1997). Individuals 
with SAD may process information in such a way as to confirm their fear of being 
negatively evaluated or being rejected, which may contribute to the reinforcement of 
beliefs (e.g., “I have to make a good impression”), as well as behaviors (e.g., avoidance 
of social situations) that maintain the disorder. Accordingly, understanding the factors 
that impact the processing of social rejection in SAD may represent a particularly 
important research area that can inform and improve existing treatments for SAD.  
16 
 
Rationale for Current Study   
The current study aimed to investigate whether oxytocin modulates responses to 
social rejection in patients with SAD. A widely-used paradigm in the study of social 
ostracism and rejection is called the Cyberball Task (Williams, Cheung, & Choi, 2000; 
Williams & Jarvis, 2006), which is a virtual ball-tossing game that can be used both as a 
manipulation of rejection and as a measure of social behavior (e.g., ball-tossing 
behavior). In Cyberball, participants are led to believe that they are playing the game with 
other online players in real time. Ostracism is induced when the players deny ball tosses 
to the participant.  
One study examined the effect of oxytocin on responses to rejection in healthy 
individuals using Cyberball (Alvares, Hickie, & Guastella, 2010). Participants were 
randomly assigned to receive either oxytocin or placebo, and were then randomized again 
to be either included or ostracized during Cyberball. Alvares and colleagues (2010) found 
that oxytocin promoted a greater willingness to re-engage socially with the other players 
when they were included in the game, but not when they were ostracized. As oxytocin 
may increase trust of in-group members (Van Ijzendoorn & Bakermans-Kranenburg, 
2012), a potential explanation for this finding is that oxytocin’s effects were moderated 
by the categorization of others into social in-groups and out-groups.  
The current study aimed to explore this in-group hypothesis by examining the 
effect of oxytocin when a cooperative player switches to less cooperative play. According 
to studies demonstrating oxytocin’s parochial effects on cooperation, that is, oxytocin 
enhances in-group, rather than out-group, cooperation (for a review, see De Dreu, 2012a), 
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it was expected that oxytocin-treated participants would continue to engage with the 
cooperative player even after the switch, compared to placebo-treated participants, who 
would adapt their behavior to toss fewer balls to this player after the switch (Hypothesis 
1).  
It was also expected that oxytocin-treated participants would provide greater 
ratings of trust toward the cooperative player, compared to placebo-treated participants 
(Hypothesis 2). A previous study investigating the effect of oxytocin on ball-tossing 
behavior during Cyberball in patients with high-functioning autism spectrum disorders 
found that patients who were given placebo did not discriminate between different play 
patterns of other players, who were programmed to display cooperative, uncooperative, 
and neutral playing profiles (Andari et al., 2010). In contrast, patients who were given 
oxytocin showed normalized and socially appropriate ball-tossing behavior that was more 
similar to that of healthy individuals. Given that the current study used a similar 
modification of Cyberball, it was hypothesized that the cooperative player would be 
particularly favored after receiving oxytocin compared to placebo.   
Furthermore, the current study aimed to investigate the effect of oxytocin on 
attentional engagement toward and disengagement from social threat cues. Previous 
research using spatial cueing paradigms such as the Posner Task has shown that patients 
with SAD have maladaptive attentional biases toward social threat cues, and may have 
difficulty disengaging from them, which may constitute a cognitive factor that maintains 
the disorder (Amir, Elias, Klumpp, & Przeworski, 2003; Mogg & Bradley, 2002). It was 
expected that oxytocin would facilitate disengagement from social threat cues (emotional 
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faces) versus social non-threat cues (neutral faces), when compared to placebo 
(Hypothesis 3). Investigating the effect of oxytocin on attentional processes would reveal 
a potential mechanism by which oxytocin exerts pro-social effects in patients with SAD.  
 
Methods and Materials 
Participants  
Sixty adult male participants consented for the study. All participants met inclusion and 
exclusion criteria. Specifically, participants were males at least 18 years of age or older, 
with a principal or co-principal diagnosis of SAD, and had a current LSAS score of ≥ 60. 
Females were excluded from the study due to complications associated with the use of 
oxytocin in pregnancy, as well as potential fluctuations of oxytocin during menstrual 
phases. No participants had significant nasal pathology (e.g., atrophic rhinitis, recurrent 
nose bleeds, history of hypophysectomy), were smokers who smoked more than 15 
cigarettes per day, had a serious medical illness, had active suicidal or homicidal ideation, 
had a current diagnosis of schizophrenia, psychotic disorder, bipolar disorder, or 
substance abuse/dependence, and no participants were concurrently taking psychotropic 
medications, except for antidepressants that had been taken at a stable dose for at least 
two weeks prior to study entry. Participants received $40 in compensation for their 
participation in the study, and additional earnings from the Cyberball Task. The study 
was approved by the Boston University Medical Center Institutional Review Board and 
was registered with the National Institutes of Health ClinicalTrials.gov Registry 
(NCT01856530).   
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Measures 
Mini Adult Diagnostic Interview Schedule for DSM-IV (Mini-ADIS-IV; DiNardo, 
Brown, & Barlow, 1994): The Mini-ADIS-IV is a brief clinician-administered, semi-
structured interview that assesses current mood and anxiety disorders. It was 
administered at the beginning of the study visit to assess eligibility for the study.  
Liebowitz Social Anxiety Scale (LSAS; Liebowitz, 1987): The LSAS is a 24-item 
semi-structured interview that assesses fear and avoidance of social situations in the past 
week. It is widely used in treatment studies for SAD. The LSAS has been validated in 
clinical samples and has high internal consistency (α = .82-.92) (Heimberg et al., 1999). 
The LSAS was used to confirm the SAD severity criterion for inclusion in the study.  
Social Interaction and Anxiety Scale (SIAS; Mattick & Clarke, 1998): The SIAS 
is a 20-item measure that assesses anxiety in social interaction situations. The SIAS has 
been shown to be a valid measure of social interaction anxiety, and has been 
demonstrated to have good internal consistency and reliability in samples of patients with 
SAD (Clark et al., 1997). The SIAS was administered before and after drug 
administration to assess levels of social interaction anxiety.  
Beck Depression Inventory-II (BDI-II; Beck, Steer, & Brown, 1996): The BDI-II 
is a widely used self-report measure of severity of depressive symptoms that are 
congruent with the diagnostic criteria of major depressive disorders in the DSM-IV. The 
BDI-II was given to assess baseline levels of depressive symptoms.  
Interpersonal Sensitivity Measure (IPSM; Boyce & Parker, 1989): The original 
IPSM is a 36-item self-report measure to assess sensitivity to rejection. The current study 
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employed a 29-item, modified version for use among SAD patients (Harb, Heimberg, 
Fresco, Schneier, & Liebowitz, 2002). It has demonstrated good internal consistency, as 
well as convergent validity with other self-report measures of social anxiety. The IPSM 
was given to examine baseline levels of rejection sensitivity.  
Experience in Close Relationships Inventory (ECR; Brennan et al., 1998): The 
ECR is a 36-item self-report questionnaire that measures attachment anxiety and 
avoidance in adults. It yields two subscales reflecting attachment anxiety (anxiety about 
being rejected or abandoned) and attachment avoidance (discomfort with closeness and 
intimacy). The ECR was administered at baseline to assess participants’ general 
attachment styles in close relationships. In the current study, the two subscales were not 
significantly correlated, r = -.32, n = 25, p = .12.   
Positive and Negative Affect Scales (PANAS; Watson, Clark, & Tellegen, 1988): 
The PANAS is a 20-item self-report measure of positive and negative affect, which was  
administered before and after drug administration to examine state changes in mood.  
Trust, Preference, Empathy, Perceived Rejection, and Willingness to Re-Engage 
Ratings: Participants were asked to provide ratings on a 7-point Likert scale on trust, 
preference, empathy, perceived rejection, and willingness to re-engage in another round 
of Cyberball for each of the other players in the game. This questionnaire was completed 
immediately following the Cyberball Task.  
Adverse Events Form: Participants were asked to report whether they experienced 
a negative reaction to the oxytocin and placebo nasal sprays (yes or no), and if so, to 
describe the nature of the negative reactions. In the current study, no participants 
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endorsed serious adverse events. The adverse events form was completed immediately 
following the Cyberball Task.  
Assessment of Blind Questionnaire: Participants were asked which condition they 
believe they were randomized to (oxytocin or placebo), to rate their degree of certainty, 
and to describe their reasons why.  
 
Drug 
 Investigational new drug information. Oxytocin is currently approved by the Food 
and Drug Administration (FDA) in an intravenous form for the purpose of facilitating 
childbirth. The approved dosage is approximately .5-1 mU/min, which can be increased 
to 1-2 mU/min until the desired contraction pattern has been reached. Synthetic oxytocin 
(e.g., Syntocinon® or Pitocin®) is typically administered intravenously in neonatal 
settings to induce labor. It is widely distributed throughout the extracellular fluid and 
causes uterine response almost immediately. Its removal from the blood is facilitated by 
the kidney and liver, and has a plasma half-life of approximately 1 to 6 minutes (per 
Pitocin® package insert). Intranasal delivery of oxytocin enables actions within the brain 
and produces pro-social behavioral effects in humans. Although the duration of action of 
oxytocin in the central nervous system is unclear, data from a closely-related 
neuropeptide, vasopressin, indicate that elevated CSF levels occur within 10 minutes to 
an hour, and that its duration of action may last anywhere between two to eight hours 
(Born et al., 2002). Oxytocin, however, is not approved for use in patients with SAD, and 
a nasal form of the drug is not approved. In this study, the purpose, dose, and manner of 
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administration of oxytocin are considered experimental. The current study has been 
allowed to proceed under Investigational New Drug Application (IND) #113,827. 
 Oxytocin dose and route of administration. The oxytocin and placebo nasal sprays 
used in the current investigation consisted of 24 IU of oxytocin, and were dispensed in 
metered-dose spray bottles to deliver exactly 4 IU per spray. The placebo sprays were 
identical to the oxytocin nasal sprays, except for the addition of 0.65% sodium chloride to 
the placebo nasal spray, which helped to minimize nasal irritation to the participant. The 
24 IU dose was selected for the study, as this reflects the most commonly used intranasal 
dose in previous human trials (25 out of 38 studies) (MacDonald et al., 2011).  
 
Tasks  
 Cyberball Task (Williams et al., 2000; Williams & Jarvis, 2006). Cyberball is a 
four-person computerized ball-tossing game, which was designed to manipulate 
ostracism. Participants are led to believe that they are playing with three “others” in real 
time. The program was modified to create three different behavioral profiles for the 
fictitious others. For the first 80 trials (Play Condition), Player 1 was programmed to toss 
on average 70% of his balls to the participant, whereas Player 4 tossed 30%, and Player 3 
tossed only 10% of them, to the participant. The participant was always Player 2. Each 
trial consisted of a single ball toss exchange, which was represented by a short animation 
of one player tossing the ball and another player catching the ball. The participant had the 
choice to toss the ball to a player when he received the ball from a previous trial. 
Participants were told that the purpose of the game was to obtain as many points as 
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possible, which would be converted to real monetary rewards at the end of the task. They 
were informed that they would receive 20 points ($0.20) each time a ball was tossed to 
them, and lose 10 points ($0.10) each time the ball was tossed to someone else. After 80 
trials, the behavioral profiles switched (Switch Condition), such that Player 1 was 
programmed to toss only 10% of his played balls to the participant. After the switch, the 
participant played Cyberball for another 80 trials. The decision time for the fictitious 
players was varied from trial to trial to enhance the believability of realistic play 
behavior. The participant was represented by a fourth cartoon on the computer screen 
taken from a first person perspective. The display also provided ongoing feedback for the 
participant’s total points throughout the game. Ratings of trust, empathy, preference, 
perceived rejection, and willingness to re-engage in another game of Cyberball with each 
player, were measured on a 7-point Likert scale at the end of the task. The entire task 
consisted of 160 trials in total and took approximately eight minutes to complete. 
Modified Posner Task (Posner, 1980; Posner, Snyder, & Davidson, 1980). The 
Posner Task measures attentional engagement toward and disengagement from social 
threat cues. The stimuli for this task were modified to include a set of disgust, happy, and 
neutral faces. The task consisted of 360 trials. During each trial, the participant saw a 
fixation cross. On each trial, a face (disgust, happy, or neutral) appeared within either the 
top or bottom half of the screen (the other half of the screen would remain blank) and 
then disappeared. Then, a probe (the letter “E” or “F”) appeared in the top or bottom half 
of the screen. The participant was instructed to identify the letter as quickly and 
accurately as possible by clicking the left or right mouse button (left for “E”, right for 
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“F”). Upon responding, the next trial commenced. For valid trials, the probe appeared in 
the position previously occupied by the face stimulus, whereas for invalid trials, the 
probe appeared in the empty half of the screen. Reaction times to valid and invalid trials 
reflected the participant’s attentional engagement towards threat and disengagement from 
threat, respectively. The entire task took 10 minutes to complete. 
 
Procedure  
Participants were recruited from the community using approved print and online 
advertisements, as well as from the clinic waitlist at the Center for Anxiety and Related 
Disorders. Potential participants were phone screened to ensure they met basic eligibility 
requirements for the study, and were asked not to have caffeine, alcohol, or nicotine for 
24 hours prior to the study appointment. Participants were then scheduled for a single 
visit lasting approximately four hours.  
During the study visit, participants first gave written informed consent and were 
assessed for eligibility through a diagnostic evaluation and medical screen. The 
diagnostic evaluation consisted of administration of the Mini-ADIS-IV, which was used 
to confirm diagnostic eligibility. Participants then met with the study physician to 
complete the medical screen, which consisted of assessing concurrent psychotropic 
medications, significant nasal pathology, as well as measuring vitals (e.g., blood pressure, 
pulse). Participants were then asked to complete a set of self-report questionnaires to 
collect demographic information, as well as to assess baseline levels of depression, social 
anxiety, attachment orientation, rejection sensitivity, and subjective mood.  
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Next, participants were randomly assigned to receive a nasal spray containing 
either oxytocin or placebo using a computer-generated pre-randomization sheet. The 
study was double-blind, such that neither the study physician nor the experimenter were 
aware of participants’ assigned drug condition. Using a standardized protocol, 
participants self-administered a metered-dose nasal spray with three puffs per nostril (4 
IU of oxytocin or placebo per puff) in the presence of the study physician or nurse. After 
nasal spray administration, participants’ vitals were measured again.  
Participants were then asked to sit in an isolated waiting room for 45 minutes 
before starting the computer tasks, as this reflects a standard wait period following 
intranasal oxytocin administration. After 45 minutes, participants were led to a common 
waiting area for the study, where they were told that they would have an opportunity to 
briefly meet three other study participants for the first task. The experimenter led the 
participant and three male confederates individually into the waiting area, and asked each 
participant to introduce their first name to the group. At this time, participants were 
individually led to their separate experimental rooms.  
Participants played Cyberball first, and then completed the post-Cyberball 
questionnaires, as well as other self-report questionnaires, which assessed potential 
adverse events related to the drug and their beliefs about their assigned drug condition. 
Participants then completed the modified Posner Task. The experiment concluded with a 
debriefing session.  
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Statistical Analyses  
Primary analyses. First, to address Hypotheses 1-3, a series of mixed between-
within analyses of variance (ANOVAs) were conducted to examine group effects on 
social outcomes during Cyberball, and attentional outcomes during the Posner Task. 
Specifically, Cyberball outcomes included: 1) number of balls thrown to Player 1 during 
the Play and Switch conditions, 2 (Group: oxytocin, placebo) x 2 (Time: balls tossed to 
Player 1 during Play and Switch conditions), 2) the number of balls thrown to each of the 
other players during the Play condition, 2 (Group: oxytocin, placebo) x 3 (Player: balls 
tossed to Player 1, 3, and 4), and 3) overall trust and rejection ratings for each of the 
players, 2 (Group: oxytocin, placebo) x 3 Player (trust and rejection ratings for Player 1, 
3, and 4). On the Posner Task, faster response latencies when detecting validly cued 
targets following disgust faces indicated an attentional “engagement” or bias toward 
threat-relevant information. Slower response latencies when detecting invalidly cued 
targets following disgust faces indicated difficulty disengaging attention away from 
threat-relevant information. To examine the effect of oxytocin on attentional engagement 
and disengagement by face type, a mixed 2 (Group: oxytocin, placebo) x 2 (Cue Type: 
valid, invalid) x 3 (Face Type: disgust, neutral, happy) ANOVA was conducted with 
repeated measurement on the last two factors. To examine group differences on 
demographic characteristics and baseline clinical measures, t-tests were conducted for 
continuous variables and chi-square tests were conducted for categorical variables. Given 
that there were no significant differences in age and social anxiety symptom severity 
between groups, and that inclusion of covariates would significantly reduce test power, 
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we did not control for covariates in the analyses. Thus, covariates were not included in 
the reported analyses moving forward.  
Secondary analyses. A regression approach was adopted to explore the 
interactions between drug and continuous moderators (rejection sensitivity, attachment 
anxiety, and attachment avoidance) on Cyberball outcomes (ball-tossing behavior, ratings 
of trust and rejection), as well as outcomes during the Posner Task (attentional 
engagement and disengagement scores for each face type and cue type). Hierarchical 
regression analyses were conducted on all participants in the sample to examine the 
effects of drug group (dummy coded: 1 = oxytocin and 0 = placebo), and mean-centered 
rejection sensitivity (entered in step 1), and their two-way interaction (entered as a 
product term in step 2), on each outcome. The regressions were then repeated to examine 
the effects of drug grou `p (dummy coded: 1 = oxytocin and 0 = placebo), and 
mean-centered attachment anxiety and attachment avoidance (entered in step 1), and their 
two- and three-way interactions (entered as product terms in steps 2 and 3, respectively) 
on the same outcomes. Regression analyses were followed up by generating predicted 
values based on each regression equation and plotting XY graphs to examine the nature 
of the interaction. 
Manipulation check. A separate analysis was conducted to ensure that Cyberball 
successfully manipulated different player profiles by examining whether participants 
discriminated between the behavioral profiles. Participants’ perceptions of each player’s 
behavior during the Play and Switch conditions were measured on a 4-point Likert scale 
(e.g., “For Player 1, how much did he play with you at first?). A repeated measures 
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ANOVA was conducted for each half of the game with ratings of each player’s behavior 
as the within-subjects factor.  
 
Results 
Demographic Characteristics 
Six participants were excluded due to being ineligible for the study (three did not 
have SAD, two met criteria for substance dependence, and one had a principal diagnosis 
of posttraumatic stress disorder). The final sample included 54 participants (age range = 
18-45 years). Two participants did not complete the Cyberball Task due to technical 
difficulties. This sample size was selected to allow adequate power (β = .80) to detect a 
medium effect size (f = .25) at an alpha level of .05. Chi-square and t-tests showed no 
differences between groups in demographic or baseline clinical characteristics (all p’s > 
.05) (See Table 1). The most common comorbid diagnosis was major depression (18.5%), 
followed by generalized anxiety disorder (16.7%), and panic disorder with agoraphobia 
(7.4%). 
 
Primary Analyses 
Effect on cooperation. Oxytocin, relative to placebo, did not lead to continued 
cooperation with Player 1 across the two conditions during the game, as there was no 
significant Group x Time interaction, Wilks’ Lambda = 1.00, F(1,50) = .02, p = .88, ηp
2
 = 
.00 (Hypothesis 1). Both groups showed a reduction in ball tosses to Player 1 during the 
game, Wilks’ Lambda = .66, F(1,50) = 26.37, p < .001, ηp
2 
= .34, but this did not differ 
29 
 
by group, F(1,50) = .70, p = .41, ηp
2 
= .01. In addition, oxytocin, relative to placebo, was 
not significantly associated with more throws to Player 1 during the Play condition, 
compared to other players, as there was no significant Group x Player interaction, Wilks’ 
Lambda = .99, F(2, 49) = .24, p = .78, ηp
2 
= .01. Both groups threw significantly more 
balls to Player 1, compared to other players, Wilks’ Lambda = .47, F(2,49) = 27.32, p < 
.001, ηp
2 
= .53, but this did not differ by group, F(1,50) = .32, p = .57, ηp
2 
= .01.  
Effect on perceived trust and rejection. Oxytocin, relative to placebo, did not 
significantly impact trust ratings for Player 1, compared to other players, Wilks’ Lambda 
= .98, F(2,47) = .44, p = .64, ηp
2 
= .02 (Hypothesis 2). In addition, oxytocin, relative to 
placebo, did not significantly impact perceived rejection ratings from Player 1, compared 
to other players, Wilks’ Lambda = .99, F(2,47) = .27, p = .77, ηp
2 
 = .01. However, those 
who received oxytocin reported lower ratings of overall rejection from all players during 
Cyberball, relative to those who received placebo, F(1,48) = 3.98, p = .05, ηp
2 
= .08.  
Manipulation check. It was determined whether Cyberball successfully 
manipulated different behavioral profiles for the other players during the Play and Switch 
conditions of the game. Nine (17.3%) out of 52 participants who completed Cyberball 
reported that they did not notice a change in any player’s behavior during the game. 
However, of those who did notice a change, participants reported that Player 1 played the 
most with them at first, Wilks’ Lambda = .66, F(2,44) = 11.15, p < .001, ηp
2 
= .34, and 
that there was no significant difference between the other players’ behavior later on 
during the Switch condition of the game, Wilks’ Lambda = .95, F(2,44) = 1.28, p = .29, 
ηp
2 
= .06. This suggests that the manipulation was successful, as participants 
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discriminated that Player 1 played with them the most initially, and that this was no 
longer true later on.  
Effect on attentional engagement and disengagement of social cues. First, 
response times for inaccurate trials were eliminated. Inaccurate trials consisted of trials 
where the probe was the letter “E” and the participant pressed the right mouse button or 
vice versa. This resulted in elimination of 2% of the trials. Response latencies less than 
360 ms and greater than 2200 ms were considered outliers and eliminated from the 
analysis. Idiographic standardization of response times was then conducted, and response 
latencies from trials reflecting two standard deviations above or below an individual’s 
personal mean were eliminated from the analysis, which resulted in elimination of 4% of 
the trials. Finally, for each participant, a mean response time was calculated for each face 
type and cue condition (See Table 4).  
Oxytocin, relative to placebo, was not associated with facilitated attentional 
engagement or disengagement scores for any face type, as there was no significant 
interaction of Group x Cue Type x Face Type, Wilks’ Lambda = .93, F(2,50) = .44, p = 
.65 (Hypothesis 3). We then conducted separate Group x Cue Type analyses for each face 
type, and found no significant interactions: disgust faces, Wilks’ Lambda = 1.00, F(1,51) 
= .15, p = .70; happy faces, Wilks’ Lambda = 1.00, F(1,51) = .09, p = .77; and, neutral 
faces, Wilks’ Lambda = .99, F(1,51) = .70, p = .41. There were no other significant main 
effects.  
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Secondary Analyses 
Effect on cooperation. Regression analyses revealed a significant Group x 
Attachment Avoidance interaction on difference scores in balls tossed to Player 1 during 
Cyberball, B = 6.90, t(19) = 2.11, p = .05. The attachment interaction terms contributed to 
the overall model by explaining an additional 19.9% of the variance in ball tosses, F 
change (2,19) = 2.72, p = .09. Among participants with low Attachment Avoidance, 
oxytocin resulted in smaller difference scores in the number of balls tossed to Player 1 
between the Play and Switch conditions compared to placebo, which suggested greater 
cooperation with Player 1 (Figure 1). Among participants with high Attachment 
Avoidance, oxytocin resulted in greater difference scores across the Cyberball conditions 
compared to placebo, which suggested decreased cooperation with Player 1. There was 
no significant Group x Attachment Anxiety interaction on difference scores in balls 
tossed to Player 1, B = -.91, t(19) = -.32, p = .75, as well as no significant Group x 
Rejection Sensitivity interaction on difference scores in balls tossed to Player 1, B = .30, 
t(42) = 1.23, p = .23.  
Effect on perceived trust and rejection. Regression analyses showed a significant 
Group x Rejection Sensitivity interaction on overall ratings of perceived rejection from 
other players during Cyberball, B = .07, t(42) = 2.44, p = .02. The interaction effect 
explained a significant portion of variance in rejection ratings, R
2
 change = .12, F change 
(1,42) = 5.97, p = .02. Among participants with high Rejection Sensitivity, oxytocin 
resulted in greater overall perceived rejection from the other players, compared to 
placebo (Figure 2). In contrast, among those with low Rejection Sensitivity, oxytocin 
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resulted in lower levels of overall perceived rejection from other players, compared to 
placebo. There was no significant Group x Rejection Sensitivity interaction on trust, B = -
.01, t(42) = -.16, p = .87. There was also no significant Group x Attachment Anxiety 
interaction on trust, B = -.004, t(19) = -.02, p = .99, or rejection, B = .37, t(19) = .84, p = 
.41, and no significant Group x Attachment Avoidance interaction on trust, B = .08, t(19) 
= .26, p = .80, or rejection, B = .41, t(19) = .82, p = .42.  
Effect on attentional engagement and disengagement of social cues. Regression 
analyses showed a significant Group x Attachment Avoidance interaction on engagement 
scores for disgust faces, B = -106.12, t(18) = -2.34, p = .03, and neutral faces, B = -
102.47, t(18) = -2.07, p = .05, but not for happy faces, B = -81.30, t(18) = -1.52, p = .15. 
When given oxytocin, individuals with high Attachment Avoidance responded faster to 
validly cued disgust faces and neutral faces, whereas individuals with low Attachment 
Avoidance took longer to respond (Figure 4). For disengagement scores, there was a 
trend toward a group difference for the Group x Attachment Avoidance interaction for all 
face types: disgust faces, B = -106.87, t(19) = -1.98, p = .06; neutral faces, B = -99.14, 
t(19) = -1.82, p = .09; and, happy faces, B = -93.32, t(19) = -2.03, p = .06. When given 
oxytocin, individuals with high Attachment Avoidance responded faster to invalidly cued 
disgust, neutral, and happy faces, whereas individuals with low Attachment Avoidance 
took longer to respond. Although the product terms explained an additional portion of 
variance in engagement and disengagement scores, none of the changes in R
2
 were 
significant, all p’s > .05. There was no significant Group x Attachment Anxiety 
interaction on engagement scores for disgust faces, B = -56.84, t(18) = -1.46, p = .16, 
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neutral faces, B = -35.58, t(18) = -.81, p = .43, or happy faces, B = -2.66, t(18) = -.06, p = 
.96. There was also no significant Group x Attachment Anxiety interaction on 
disengagement scores for disgust faces, B = -16.62, t(19) = -.36, p = .73, neutral faces, B 
= -25.18, t(19) = -.53, p = .60, or happy faces, B = -28.64, t(19) = -.72, p = .48.  
Furthermore, although regression analyses showed no significant interactions 
between Group x Rejection Sensitivity on engagement and disengagement scores for any 
face type (all p’s > .05), there was a significant effect of Rejection Sensitivity on 
disengagement from happy faces, B = 4.69, t(47) = 2.00, p = .05, suggesting that greater 
rejection sensitivity was associated with longer response latencies for invalid trials 
involving happy faces. 
 
Self-Reported Mood and Social Interaction Anxiety  
Oxytocin did not significantly reduce self-reported negative mood, positive mood, 
or social interaction anxiety, as all of these interaction effects were non-significant 
(negative mood: Wilks’ Lambda = 1.00, F(1,50) = .23, p = .63, ηp
2 
= .01; positive mood: 
Wilks’ Lambda = .99, F(1,51) = .57, p = .45, ηp
2 
= .01; social interaction anxiety: Wilks’ 
Lambda = 1.00, F(1,23) = .01, p = .91, ηp
2 
= .001). Interestingly, both groups showed 
improved positive mood during Cyberball, Wilks’ Lambda = .84, F(1,51) = 9.61, p = 
.003, ηp
2 
= .16, but this did not differ by group, F(1,51) = .74, p = .39, ηp
2
 = .01.  
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Discussion 
The current study investigated the effect of a single administration of oxytocin on 
pro-social outcomes among individuals with SAD. Specifically, the current study 
assessed how oxytocin impacted cooperative behavior during an online ball-tossing 
game, and whether oxytocin modulated attentional processes involving social threat cues.  
Hypotheses 1 and 2. During Cyberball, Hypotheses 1 and 2 were partially 
supported. It was hypothesized that compared to placebo, oxytocin would contribute to 
continued cooperation with Player 1, even after the switch in his behavior. There were 
two main findings with respect to these hypotheses. First, oxytocin- and placebo-treated 
participants did not differ significantly in terms of balls thrown to Player 1 during the 
Play condition, nor in terms of trust ratings for Player 1. However, oxytocin was 
associated with greater cooperation with Player 1 after the switch, for participants who 
were low in attachment avoidance. Conversely, oxytocin was associated with less 
cooperation with Player 1 after the switch for participants who were high in attachment 
avoidance. Second, participants who were given oxytocin reported less rejection from 
other players during the game, compared to those who were given placebo, and it 
appeared that this effect was qualified by a significant interaction effect. Oxytocin led to 
greater subjective feelings of rejection from players when individuals were highly 
rejection sensitive, whereas it appeared to protect from feeling rejected for individuals 
who were low in rejection sensitivity.  
There are many possibilities to explain the finding that oxytocin impacted 
cooperative behavior with Player 1 only for those with low attachment avoidance. First, 
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mounting research suggests that oxytocin motivates in-group favoritism and parochial 
cooperation, but not for out-groups (De Dreu, 2012a; Van Ijzendoorn & Bakermans-
Kranenburg, 2012). Studies additionally suggest that oxytocin appears to help 
discriminate between familiar and unfamiliar others (Macbeth et al., 2009; Rimmele, 
Hediger, Heinrichs, & Klaver, 2009), although it remains unclear whether oxytocin 
specifically mediates the categorization of others into in-groups and out-groups (De Dreu, 
2012a). In the current study, given that social categorization of players during Cyberball 
was not measured, it is difficult to know whether this mediated greater cooperation with 
Player 1 for individuals who were low in attachment avoidance. However, results from 
the manipulation check suggest that the majority of participants (83%) noticed that Player 
1 played with them initially the most out of all of the players. Player 1 may have been 
associated with an in-group status once a ball-tossing alliance was formed early on in the 
game, and oxytocin may have enhanced the salience of this behavior, particularly for 
individuals with low attachment avoidance, who may have otherwise ignored Player 1’s 
efforts to engage. It therefore remains a possibility that oxytocin motivated individuals 
with low attachment avoidance to be more cooperative with Player 1 after the switch via 
a social categorization or social salience enhancing mechanism. It is notable that the 
analyses were repeated while omitting participants for whom the manipulation did not 
work, and there was no change in the effects of oxytocin on the primary analyses or 
moderator analyses during Cyberball.  
Second, this finding is consistent with previous research demonstrating that 
oxytocin’s effects are dependent on individual difference factors, including attachment 
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orientation. For example, Bartz and colleagues (2011) found that across their entire 
sample of individuals with BPD and healthy controls, attachment orientation moderated 
the effects of oxytocin on trust and cooperative behavior. In that study, oxytocin impaired 
trust for individuals with high attachment anxiety, whereas in the current study, oxytocin 
had no effect for those with high attachment anxiety but rather impaired cooperation for 
those with high attachment avoidance. The divergent effects of oxytocin, as a function of 
attachment style, clearly require further research. It is possible that other contextual 
factors may play a role, such as the availability of social information (Declerck, Boone, 
& Kiyonari, 2010).  
Third, it may be possible in the current study that oxytocin’s effects were 
mediated by reduced betrayal aversion, as this has been shown in previous research for 
individuals with high attachment avoidance (De Dreu, 2012b). In one study (De Dreu, 
2012b), 77 healthy males (mean age = 20.81 years) with high attachment avoidance 
cooperated significantly more during an anonymous social dilemma task, gave higher 
ratings of trust toward their partner during the task, and displayed lower ratings on a 
measure of betrayal aversion, when they were given oxytocin compared to placebo, 
whereas participants with low attachment avoidance showed reverse findings on each 
outcome. In addition, attachment anxiety did not moderate the effects of oxytocin on any 
outcome. It is noteworthy that in the current sample, low scores on the attachment 
avoidance subscale reflected scores within the average range reported in other samples 
(Brennan et al., 1998), which highlights the relatively greater attachment insecurity 
characteristic of the current sample. Findings from De Dreu (2012b), which are consistent 
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with the results from the current study, suggest that oxytocin differentially benefits those 
who are fearful of intimacy and dependency (attachment avoidance) than those who are 
fearful of rejection and abandonment from others (attachment anxiety). Although the 
current data suggest that oxytocin did not increase trust toward any of the other players 
during the game, trust was measured by a single self-report item in the current study. 
Therefore, the construct of trust was not well-defined and thus not well-measured in the 
current study. This leaves open the possibility that oxytocin may impact different types of 
trust more than others (e.g., relationship trust versus financial trust).  
Finally, there is a body of research comparing the effects of oxytocin 
administration between healthy individuals and psychiatric populations, which has shown 
that oxytocin may only be favorable for individuals who stand to gain in terms of 
socioemotional functioning, but not favorable for individuals who already function 
adequately (for a review, see Olff et al., 2013). For example, in studies examining the 
effect of intranasal oxytocin in patients with SAD, results have demonstrated that 
oxytocin modulates amygdala activity in response to emotional faces in the SAD group, 
but not in the healthy control group (Labuschagne et al., 2010; Labuschagne et al., 2011). 
In addition, evidence suggests that patients with SAD may have a dysregulated oxytocin 
system, as they displayed lower levels of plasma oxytocin after playing the Trust Game, 
when compared with controls (Hoge et al., 2012). Therefore, it may be possible that 
oxytocin is dysregulated in psychiatric populations such as SAD, and that patients may 
respond differently to exogenously administered oxytocin than healthy individuals. 
Without a healthy control group in the current study, it is impossible to compare the 
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effects of oxytocin in both groups. Further research is needed to explore these 
possibilities.  
Interestingly, oxytocin did not universally benefit a group of severely 
symptomatic, highly rejection sensitive SAD patients, given that only those with low 
baseline levels of rejection sensitivity and attachment avoidance showed improved social 
outcomes during Cyberball after receiving oxytocin, relative to placebo. This finding is 
consistent with the amplification hypothesis, that for some individuals, oxytocin may 
amplify pre-existing interpersonal schemas, whether positive or negative (Bartz et al., 
2011). The sample mean on the IPSM was 82.91, which is comparable to reported norms 
in SAD samples on this measure (Harb et al., 2001). This finding may be consistent with  
the notion that oxytocin may have strongest effects for those within a moderate range of 
abnormal functioning, but may have no benefits beyond that range. Furthermore, a recent 
study (Declerck, Boone, & Kiyonari, 2013) demonstrating oxytocin’s amplification effect 
showed that individuals with a pro-self (compared to pro-social) value orientation 
displayed exaggerated self-interested behaviors during a social dilemma game when 
given oxytocin, but only in the anonymous condition. When given the opportunity to 
meet their partner beforehand, these individuals showed enhanced cooperative behavior 
when given oxytocin. Thus, it appears that oxytocin interacts with multiple contextual 
and individual factors. In the current study, oxytocin’s effect on existing interpersonal 
schemas related to rejection sensitivity may be confounded by other contextual factors 
that were not measured or controlled (e.g., availability of social information).   
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Hypothesis 3. During the Posner Task, Hypothesis 3 was partially supported. It 
was expected that oxytocin would facilitate disengagement from emotional threat cues 
versus emotional non-threat cues, relative to placebo. Oxytocin did not impact attentional 
engagement or disengagement of social cues when comparing between threat (disgust) 
versus non-threat (neutral) cues. However, for individuals with high attachment 
avoidance, oxytocin did speed up response times for responding to face types when 
examined separately. For these individuals, oxytocin not only facilitated disengagement 
from all emotional cues (although this was not statistically significant), whether they 
depicted disgust, neutral, or happy faces, but also appeared to speed up detection of 
disgust and neutral faces. No such pattern was found for individuals with high attachment 
anxiety. Interestingly, after removing participants from the analyses for whom the 
manipulation failed during Cyberball, there was a robust moderation effect of oxytocin 
for all face types and cue types for individuals with high attachment avoidance.   
There are many possible explanations for this finding. First, as already described 
above, this finding is consistent with research showing that oxytocin may benefit 
individuals within a certain range of abnormal social or emotional functioning. More 
broadly, this finding contributes to the existing literature on how oxytocin alters social 
attention (Guastella & MacLeod, 2012), as previous research has shown that oxytocin has 
dual effects on social cognition: oxytocin may enhance the salience of social cues in the 
immediate social environment (Prehn et al., 2013), and it may also reduce attention to 
social threat (such as unfamiliar, emotional faces), which thereby reduces vigilance 
toward such threat (Ebitz, Watson, & Platt, 2013; Ellenbogen et al., 2012). The current 
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findings support the latter hypothesis and provide further evidence that oxytocin may 
normalize the dysfunctional attentional processes associated with high attachment 
avoidance by facilitating disengagement from social cues.  
Second, oxytocin may lead to biased recall of information that is congruent with 
one’s interpersonal schemas. A previous study examining the effect of oxytocin on 
retrospective recollections of maternal care and closeness found that individual 
differences in attachment anxiety moderated oxytocin’s effects, such that those with high 
attachment anxiety remembered their mother as being less caring and less close after 
receiving oxytocin relative to placebo (Bartz et al., 2010). Consistent with this finding, 
the current results suggest that individuals with insecure attachment are biased to detect 
social stimuli faster after receiving oxytocin. One may speculate that this sets in motion a 
“priming” effect, such that oxytocin activates information congruent with one’s 
attachment representations and that individuals with insecure attachment styles may have 
negative attachment schemas (Bartz et al., 2010). The current findings also suggest that 
for individuals with high attachment avoidance, oxytocin facilitated disengagement from 
all social cues, regardless of emotional valence, which contrasts with previous studies 
showing that oxytocin may specifically bias information processing in a positive 
direction. For example, oxytocin may improve the encoding of positive social memories 
(Guastella, Mitchell, & Mathews, 2008). Further research is needed to test whether 
oxytocin primes attachment-relevant memories using implicit paradigms, and to 
determine whether these discrepant findings may be due to differential effects of oxytocin 
at various levels of information processing (e.g., attention versus memory). Research is 
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also needed to test whether cognitive mechanisms such as selective attention or biased 
recall of social information mediates oxytocin’s effects on pro-social behavior, as it 
remains unclear how these mechanisms translate to behavioral outcomes.  
Lastly, these findings join a body of research showing that oxytocin promotes a 
flexible gaze pattern (Ellenbogen et al., 2012; Guastella et al., 2008). This explanation 
may be the most parsimonious, and may help to reconcile the discrepancies between 
findings on divergent effects of oxytocin on attentional processes. Results from the 
current study suggest that oxytocin facilitates both the detection and disengagement of 
social cues, which is consistent with prior work demonstrating that oxytocin enhances 
attentional shifting to and from emotional faces (Ellenbogen et al., 2012), and that 
oxytocin increases eye gaze as well as the number of fixations toward the eye region of 
faces (Domes, Steiner, et al., 2013; Guastella et al., 2008). In addition, other studies have 
documented that oxytocin facilitates eye gaze even toward neutral faces, as this may 
reflect one’s efforts to explore changes in others’ facial expressions, as they become less 
ambiguous (Domes, Steiner, et al., 2013). Thus, oxytocin’s effects on attention may not 
be strictly valence-based, but depend on the social context, and the motivations derived 
from it. Perhaps oxytocin’s regulation of attentional shifting, as reflected in the current 
study findings, has evolved to be particularly adaptive in situations where social threat is 
ambiguous (e.g., meeting strangers, entering novel contexts). Flexible attentional shifting 
thus may have two important functions: one, to monitor changes in social threat across 
the social milieu, and two, to reduce a persistent state of vigilance or gaze toward 
potential threats, which would promote cooperation with others. Especially in light of 
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evidence that individuals with SAD may have difficulty disengaging their attention from 
social threat cues (Amir et al., 2003), the current findings suggest that intranasal oxytocin 
may benefit individuals with SAD by promoting more flexible attentional patterns.  
 
General Discussion 
The current study highlights several major themes within the oxytocin literature 
and brings to bear important areas for further research. First, results from both study tasks 
revealed that oxytocin’s effects were dependent on individual difference factors, such as 
rejection sensitivity and attachment orientation. These findings contribute additional 
evidence demonstrating that oxytocin has divergent effects and may not have universal 
benefits across individuals (Bartz et al., 2011). More broadly, they suggest that one’s pre-
existing beliefs and expectations about others play a role in determining how oxytocin 
facilitates or hinders social cognition and behavior.  
Future research may benefit from clarifying similarities and differences between 
certain individual factors, such as attachment style, rejection sensitivity, and social 
anxiety, in order to better examine the specificity of oxytocin’s effects. Although the 
moderators in the current study all describe various interpersonal styles in the social 
domain, they have important differences. For example, attachment anxiety and rejection 
sensitivity may overlap with regard to fear of interpersonal rejection and hypervigilance 
of social threat cues. However, they may differ in terms of underlying motivational need 
states and the reference group. Attachment anxiety may reflect a specific need to be loved 
by a close other, whereas rejection sensitivity may reflect a broader construct reflecting a 
43 
 
need to belong and be included by a more general group. Thus, to refine our 
understanding of oxytocin’s effects, it may be important to clarify these constructs and 
distinguish them in future investigations. Given the strong evidence for individual 
variation in response to oxytocin, future research may also benefit from employing 
within-subject crossover designs rather than between-subject designs.  
Second, a major theme in the oxytocin literature is the external validity of 
available studies. Investigations span the full spectrum, from studies examining how 
oxytocin modulates basic social cognitive processes using single-dose administrations to 
studies examining how chronic, multiple administrations of oxytocin impact social and 
psychiatric outcomes. Aside from disparities in terms of dose amount and dose 
frequency, studies have varied widely in terms of sample characteristics. Typically, 
studies include healthy young males between the ages of 18-45 without any medical or 
psychiatric conditions. In terms of clinical research studies, they differ significantly with 
regard to comorbidities included in the sample, as well as use of concurrent medications. 
Additionally, studies are disparate in terms of methodology (e.g., study design, 
experimental procedures). The experimental tasks vary in terms of task demands, which 
may impact participants’ motivation and impose varying amounts of cognitive load 
during the task.  
Of all of the threats to external validity in published studies, perhaps the two 
greatest threats involve the sample selection biases, and the generalizability of results 
from experimentally-controlled laboratory paradigms. The age and sex bias in studies is 
especially problematic in light of data showing sex differences in plasma oxytocin levels 
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(Ozsoy, Esel, & Kula, 2009; Weisman, Zagoory-Sharon, Schneiderman, Gordon, & 
Feldman, 2012), sex differences in amygdala reactivity after oxytocin administration 
(Domes et al., 2007; Domes et al., 2010), and age-related differences in the association 
between oxytocin receptor polymorphisms and brain activations during an emotional face 
processing task (Ebner, Maura, MacDonald, Westberg, & Fischer, 2013). Our sample 
included only six participants older than 30, and within this older age group, a scatterplot 
of cooperation scores during Cyberball showed no evidence of age-related effects. 
Furthermore, studies frequently employ laboratory-based paradigms to test cognitive and 
behavioral outcomes, such as the well-known Trust Game. It is unclear how well these 
paradigms capture social dilemmas as they occur in the real world and whether results 
would translate to meaningful behavior change. Additionally, Cyberball was used to 
measure social cooperation in a relatively anonymous manner, and reflects only one facet 
of pro-social behavior, a construct with multiple forms and levels (Penner, Dovidio, 
Piliavin, & Schroeder, 2005). Whether the current findings translate to social cooperation 
in one’s personal relationships or in the workplace, where behavior is determined by 
multiple complex factors impacting social motivation and judgments, such as the 
presence of more social information, social desirability characteristics, and the influence 
of potential future interactions, is still subject to empirical investigation.  
Third, the current study begs the question of potential mechanisms of action of 
oxytocin. While it is clear that oxytocin is not a universal anxiolytic, more research is 
needed to understand whom it works for and under what conditions. Research has begun 
to identify some potential moderators of oxytocin’s effects, which attempt to address the 
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question of when oxytocin has effects, such as social versus non-social contexts 
(Heinrichs et al., 2003), familiarity (Macbeth et al., 2009; Rimmele et al., 2009), in-group 
versus out-group status (De Dreu, 2012a), individual difference factors (e.g., sex, age, 
attachment history, psychiatric status, genetics, social value orientation, etc.; Chen et al., 
2011; Declerck et al., 2013; MacDonald et al., 2013; McQuaid, McInnis, Stead, 
Matheson, & Anisman, 2013), and the presence of social information and social 
incentives (Declerck et al., 2010). These studies have shown that under certain 
circumstances, oxytocin may either promote or hinder social cognition and behavior, or 
even may reach a ceiling effect and show no effects (Guastella et al., 2010).  
With regard to mediators, fewer studies have examined mediation, which attempts 
to answer the question of how oxytocin has effects. Neuroimaging studies have shown 
that oxytocin reduces amygdala activation to unpleasant stimuli (Kirsch et al., 2005) and 
to human faces regardless of valence (Domes et al., 2007), which suggests that oxytocin’s 
anxiolytic effects are potentially mediated by the amygdala. A more recent study found 
that oxytocin’s divergent effects on attention and eye gaze may be explained by 
oxytocin’s differential regulation of amygdala subregions (Gamer et al., 2010). 
Specifically, investigators found that consistent with earlier findings, oxytocin attenuated 
activation in the lateral and dorsal regions of the anterior amygdala when attending to 
fearful faces, but also enhanced activation in this area for happy faces. Furthermore, 
oxytocin increased reflexive gaze shifts toward the eye region of faces regardless of 
emotional expression, which was correlated with increased (rather than decreased) 
activation in the posterior amygdala, as well as enhanced functional coupling of that 
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region to the superior colliculi. These findings suggest that oxytocin regulates attentional 
mechanisms in a valence-dependent manner, such that up-regulation of the posterior 
amygdala may actually enhance gaze patterns and improve processing of socially 
relevant information. Indeed, one may speculate from the current findings whether the 
attentional changes caused by oxytocin correlated with reliable, functional changes at the 
neural level, specifically in these subregions of the amygdala. Future research should 
expand upon this line of investigation by honing in on attentional constructs that have 
relatively clear neurobiological underpinnings, such as attentional biases and reflexive 
eye gaze shifts, in order to better understand oxytocin’s mechanisms. It will also be 
especially important to replicate these data in clinical populations such as SAD to better 
inform treatment.  
Lastly, a major theme stemming from the oxytocin literature is the application of 
findings to mental health. Perhaps the primary question of clinical relevance is the 
clinical utility and predictive value of oxytocin in a treatment context. The current study 
has important clinical implications, as the results suggest that oxytocin may improve 
social cooperation, and that oxytocin may promote flexible attentional awareness, for at 
least some individuals with SAD. However, for other individuals, the results also suggest 
that oxytocin may hinder social cooperation, as well as increase subjective feelings of 
rejection during social interactions. Taken together, the study findings tell a cautionary 
tale about oxytocin’s direct applications to SAD. Especially in the absence of a healthy 
control group in the current study, it cannot be concluded that the results would be the 
same in healthy individuals.  
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The clinical implications for the use of intranasal oxytocin in individuals with 
SAD fall into two major questions of clinical relevance—one, whether oxytocin can be 
used to augment treatment, and two, whether oxytocin can be used to predict treatment 
response. The first question raises the issue of whether oxytocin can augment 
psychological treatments in the same way as cognitive enhancers, which are a class of 
pharmacologic agents thought to facilitate learning processes such as fear acquisition, 
fear extinction, and memory consolidation (Hofmann, Fang, & Gutner, 2013). Given that 
fear extinction is a core learning process of exposure-based therapies for SAD, oxytocin 
may serve as a potential cognitive enhancer for SAD if it can be shown that it modulates 
fear-related learning. Indeed, studies have demonstrated that oxytocin differentially 
impacts fear extinction, depending on timing of administration, as some animal studies 
have shown that microinfusion of oxytocin prior to fear conditioning facilitated 
extinction, but not when administered before extinction training (Toth et al., 2012). Other 
studies have revealed that injecting oxytocin in the basolateral amygdala before fear 
conditioning may increase fear responding in rats (Lahoud & Maroun, 2013). In healthy 
humans, one study examining the effect of intranasal oxytocin when administered prior to 
extinction training found that oxytocin did not facilitate fear extinction compared to 
placebo, with both groups showing reduced responding (Acheson et al., 2013). However, 
oxytocin did facilitate extinction recall, which was measured 24 hours later. Taken 
together, these studies suggest that oxytocin may impact fear extinction in a time-
dependent manner. Oxytocin therefore has potential to augment extinction-based 
treatments for SAD. Specifically, it remains unknown whether oxytocin speeds up 
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extinction learning, which may reduce the number of treatment sessions needed, or 
whether oxytocin facilitates the consolidation of extinction memories for effective 
exposures, which may enable patients to engage more fully in exposures.  
Future research should explore these possibilities, and further examine the impact 
of timing of administration on extinction learning in patients with SAD. More research 
into the neural correlates of oxytocin’s effects may also advance our understanding of the 
specificity of oxytocin’s role in regulating fear. In addition, it will be important for future 
research to clarify any differences between acute and chronic administrations of oxytocin, 
and oxytocin’s optimal dose and dosing frequency, before application to treatment for 
SAD.  
The second question refers to oxytocin’s potential to predict treatment response, 
and its utility as a candidate endophenotype for SAD. There is emerging evidence that 
oxytocin modulates dysfunctional fear circuitry associated with SAD, as intranasal 
oxytocin appears to attenuate hyperactivity in the amygdala to fearful faces (Labuschagne 
et al., 2010), and in the medial prefrontal cortex and dorsal anterior cingulate regions to 
sad faces in individuals with SAD, to levels similar to that of healthy controls 
(Labuschagne et al., 2011). These findings suggest that oxytocin may normalize 
abnormal neural activation patterns during emotional processing in SAD, and give rise to 
a new hypothesis that oxytocin may improve emotion regulation by enhancing functional 
connectivity between the medial prefrontal cortex and amygdala. Furthermore, research 
on common polymorphisms of the oxytocin receptor gene has demonstrated associations 
between oxytocin genotypes and certain behavioral outcomes, such as depressive 
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symptomatology (McQuaid et al., 2013), psychopathy (Dadds, Moul, et al., 2013), and 
pervasive aggressive behavior (Malik, Zai, Abu, Nowrouzi, & Beitchman, 2012). Thus, it 
may be possible that certain oxytocin and oxytocin receptor gene variants confer risk, or 
interact with environmental stressors to confer risk for social deficits. With regard to 
prediction of treatment response, research in this area is extremely limited; however, 
available evidence suggests that variations of the oxytocin and oxytocin receptor genes 
are associated with clozapine treatment response and symptom severity in schizophrenia 
(Souza, de Luca, Meltzer, Lieberman, & Kennedy, 2010). It remains to be tested whether 
oxytocin’s effect on baseline neural activation patterns or whether genotyping of 
oxytocin and oxytocin receptor polymorphisms prior to treatment may reliably predict 
treatment response in SAD. Given the promising research showing the beneficial role of 
oxytocin in modulating abnormalities in social information processing across emotional 
disorders thus far, its utility as a baseline assessment tool for prediction of treatment 
response may be a valuable avenue of exploration.  
The current study findings should be interpreted in the context of certain 
limitations. First, the lack of a healthy control group prohibits conclusions about 
comparisons between individuals with SAD and healthy individuals in the current study, 
particularly with regard to the effects of oxytocin. An important follow-up question will 
be to examine oxytocin’s effects in a healthy control group. Second, the current study 
findings may not generalize to females, children, or older adults, given that the sample 
consisted of relatively young adult males between the ages of 18 and 45 years old. Lastly, 
although the primary manipulation in Cyberball appeared to be noticed by the majority of 
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the sample, 17% did not notice a change in Player 1’s behavior. Conclusions are therefore 
more limited with regard to the impact of Player 1’s behavior during the game.  
 
Conclusions 
Broadly, the current study represented an innovative approach to apply the 
translation of neuroscience to clinical phenomena, in an effort to better understand the 
neurobiological underpinnings of social deficits associated with SAD. Specifically, the 
current study investigated the role of a well-known neuropeptide, oxytocin, on social 
behavior and social attentional processing in individuals with SAD. Consistent with study 
hypotheses, results suggested that intranasal oxytocin may improve social cooperation 
and promote a flexible attentional pattern toward social cues, for at least some individuals 
with SAD. An important theme from the current work, which aligned with emerging 
research on oxytocin’s effects in the central nervous system, was that oxytocin was 
highly dependent on individual difference factors. More work is needed to extend these 
findings to SAD and to better inform the pathophysiology and treatment of SAD.    
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Abstract 
Background: Previous research suggests that intranasal oxytocin may promote trust, 
social cooperation, and emotion recognition in humans. In addition, oxytocin’s effects 
may be moderated by individual difference factors. The current investigation examined 
whether oxytocin impacts cooperative behavior toward a rejecting but initially 
cooperative confederate, and whether it modulates attentional processes toward social 
stimuli, as a function of individual differences.  
Methods: Using a double-blind, placebo-controlled design, 54 individuals with SAD 
were randomly assigned to receive 24 international units (IU) of oxytocin or placebo 
nasal spray. Following drug administration, participants completed a computerized ball-
tossing game called Cyberball, which measured social cooperation toward three other 
fictitious players, who were programmed to follow different behavioral profiles reflecting 
various degrees of cooperative play. After Cyberball, participants completed a modified 
version of the Posner Task. 
Results: Oxytocin, relative to placebo, improved cooperation during Cyberball, but only 
for individuals with low attachment avoidance. Relative to placebo, oxytocin also 
amplified subjective ratings of perceived rejection for individuals with high rejection 
sensitivity. Furthermore, oxytocin, relative to placebo, led to facilitated disengagement 
from all social cues regardless of emotional valence, although this was not statistically 
significant, and speeded up detection of disgust and neutral faces, but only for individuals 
with high attachment avoidance.  
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Conclusions: These findings suggest that oxytocin may promote social cooperation, as 
well as a flexible attentional pattern toward social cues, at least for some individuals with 
SAD. Future research should address individual differences in response to oxytocin, and 
further investigate the comparative effects of oxytocin in healthy individuals. 
 
National Institutes of Health ClinicalTrials.gov Registry #NCT01856530 
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Individual Differences Moderate Oxytocin’s Effects on Pro-Social Behavior and 
Attentional Processing in Individuals with Social Anxiety Disorder 
 
Oxytocin is a nine amino acid neuropeptide, which is produced in the 
paraventricular and supraoptic nuclei of the hypothalamus. It is then secreted via the 
posterior pituitary gland into peripheral circulation or released into the central nervous 
system to act on receptors widely distributed throughout the brain, including the limbic 
system, midbrain, and brainstem. 
Traditionally, oxytocin has been examined for its role in childbirth, lactation, and 
maternal attachment. Following recent advances in translational neuroscience to deliver 
oxytocin directly to the central nervous system, studies have revealed that oxytocin has 
much broader functions in social cognition and behavior than previously thought. For 
example, intranasal delivery of oxytocin appears to promote pro-social behaviors such as 
in-group favoritism (De Dreu, Greer, Van Kleef, Shalvi, & Handgraaf, 2011), trust and 
cooperation (De Dreu, 2012b; Kosfeld, Heinrichs, Zak, Fischbacher, & Fehr, 2005), and 
emotion recognition (Schulze et al., 2011). Intranasal oxytocin also appears to have 
anxiolytic properties, as it buffers responses to social stress (Heinrichs, Baumgartner, 
Kirschbaum, & Ehlert, 2003), and dampens amygdala activity to emotional stimuli 
(Domes et al., 2007). However, recent research has shed light on the context-dependent 
and divergent effects of oxytocin, and suggests that under certain conditions, oxytocin 
may even exert anxiogenic effects. Evidence from clinical samples also reflects this 
mixed picture and highlights the moderating role of individual difference factors such as 
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attachment orientation (Bartz et al., 2011). Nevertheless, intranasal oxytocin is a 
promising agent and has major treatment implications for psychiatric disorders involving 
deficits in social functioning such as social anxiety disorder (SAD). 
Among individuals with SAD, intranasal oxytocin does not appear to reduce 
symptom severity when given as an adjunct to exposure therapy (Guastella et al., 2009). 
However, oxytocin attenuates amygdala reactivity in response to fearful faces 
(Labuschagne et al., 2010), as well as cortical hyperactivity in the medial prefrontal 
cortex to sad faces (Labuschagne et al., 2011). Evidence also points to an altered 
oxytocin system in SAD patients, as they exhibit lower levels of plasma oxytocin after a 
trust game, compared to healthy controls (Hoge et al., 2012). More research is needed to 
better understand the contexts under which oxytocin is likely to benefit patients with 
SAD. For example, oxytocin may activate motivational approach schemas in social 
situations, and may affect social information processing biases associated with SAD.  
Toward this end, the current study aimed to investigate the effect of oxytocin on 
social behavior and social attentional processing in individuals with SAD. Specifically, 
the current study assessed how oxytocin impacted cooperative behavior toward a 
rejecting but initially cooperative confederate, and whether oxytocin modulated 
attentional processing of social threat cues, both while taking into account the moderating 
impact of individual differences.  
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Methods and Materials 
Participants  
Participants were 60 males at least 18 years of age or older, with a principal or co-
principal diagnosis of SAD, and had a current Liebowitz Social Anxiety Scale (LSAS; 
Liebowitz, 1987) score of ≥ 60. Females were excluded from the study due to 
complications associated with the use of oxytocin in pregnancy, as well as potential 
fluctuations of oxytocin during menstrual phases. No participants had significant nasal 
pathology (e.g., atrophic rhinitis, recurrent nose bleeds, history of hypophysectomy), 
were smokers who smoked more than 15 cigarettes per day, had a serious medical illness, 
had active suicidal or homicidal ideation, had a current diagnosis of schizophrenia, 
psychotic disorder, bipolar disorder, or substance abuse/dependence, and no participants 
were concurrently taking psychotropic medications, except for antidepressants that had 
been taken at a stable dose for at least two weeks prior to study entry. Participants 
received $40 in compensation for their participation in the study, and additional earnings 
from the social task. The study was approved by the Boston University Medical Center 
Institutional Review Board. 
Six participants were excluded due to being ineligible for the study (three did not 
have SAD, two met criteria for substance dependence, and one had a principal diagnosis 
of posttraumatic stress disorder). The final sample included 54 participants (age range = 
18-45 years). Two participants did not complete the Cyberball Task due to technical 
difficulties. This sample size was selected to allow adequate power (β = .80) to detect a 
medium effect size (f = .25) at an alpha level of .05. Chi-square and t-tests showed no 
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differences between groups in demographic or baseline clinical characteristics (all p’s > 
.05). The most common comorbid diagnosis was major depression (18.5%), followed by 
generalized anxiety disorder (16.7%), and panic disorder with agoraphobia (7.4%). 
 
Tasks 
 Cyberball Task (Williams et al., 2000; Williams & Jarvis, 2006). Cyberball is a 
four-person computerized ball-tossing game, which was designed to manipulate 
ostracism. Participants are led to believe that they are playing with three “others” in real 
time. The program was modified to create three different behavioral profiles for the 
fictitious others. For the first 80 trials (Play Condition), Player 1 was programmed to toss 
on average 70% of his balls to the participant, whereas Player 4 tossed 30%, and Player 3 
tossed only 10% of them, to the participant. The participant was always Player 2. Each 
trial consisted of a single ball toss exchange, which was represented by a short animation 
of one player tossing the ball and another player catching the ball. The participant had the 
choice to toss the ball to a player when he received the ball from a previous trial. 
Participants were told that the purpose of the game was to obtain as many points as 
possible, by receiving 20 points each time a ball was tossed to them, and losing 10 points 
each time the ball was tossed to someone else. After 80 trials, the behavioral profiles 
switched (Switch Condition), such that Player 1 was programmed to toss only 10% of his 
played balls to the participant. After the switch, the participant played Cyberball for 
another 80 trials. The decision time for the fictitious players was varied from trial to trial 
to enhance the believability of realistic play behavior. The participant was represented by 
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a fourth cartoon on the computer screen taken from a first person perspective. The 
display also provided ongoing feedback for the participant’s total points throughout the 
game. Ratings of trust, empathy, preference, perceived rejection, and willingness to re-
engage in another game of Cyberball with each player, were measured on a 7-point Likert 
scale at the end of the task. The entire task consisted of 160 trials in total and took 
approximately eight minutes to complete. 
Modified Posner Task (Posner, 1980; Posner, Snyder, & Davidson, 1980). The 
Posner Task measures attentional engagement toward and disengagement from social 
threat cues. The stimuli for this task were modified to include a set of disgust, happy, and 
neutral faces. The task consisted of 360 trials. During each trial, the participant saw a 
fixation cross. On each trial, a face (disgust, happy, or neutral) appeared within either the 
top or bottom half of the screen (the other half of the screen would remain blank) and 
then disappeared. Then, a probe (the letter “E” or “F”) appeared in the top or bottom half 
of the screen. The participant was instructed to identify the letter as quickly and 
accurately as possible by clicking the left or right mouse button (left for “E”, right for 
“F”). Upon responding, the next trial commenced. For valid trials, the probe appeared in 
the position previously occupied by the face stimulus, whereas for invalid trials, the 
probe appeared in the empty half of the screen. Reaction times to valid and invalid trials 
reflected the participant’s attentional engagement towards threat and disengagement from 
threat, respectively. The entire task took 10 minutes to complete. 
 
 
59 
 
Drug Information 
The oxytocin and placebo nasal sprays were compounded by a local pharmacy 
under Investigational New Drug #113,827. They consisted of 24 international units (IU) 
of oxytocin, and were dispensed in metered-dose spray bottles to deliver exactly 4 IU per 
spray. The placebo sprays were identical to the oxytocin nasal sprays, except for the 
addition of 0.65% sodium chloride to the placebo nasal spray, which helped to minimize 
nasal irritation to the participant.  
 
Procedure 
Participants were recruited from the community using approved print and online 
advertisements, as well as from the waitlist of an outpatient anxiety disorders specialty 
clinic. Potential participants were phone screened to ensure that they met basic eligibility 
requirements, and were asked not to have caffeine, alcohol, or nicotine for 24 hours prior 
to the study appointment. Participants were then scheduled for a single visit lasting 
approximately four hours.  
During the study visit, participants gave written informed consent and were 
assessed for eligibility through a diagnostic evaluation using the Mini Adult Diagnostic 
Interview Schedule for DSM-IV (DiNardo, Brown, & Barlow, 1994). Participants then 
met with the study physician to complete a medical screen, which consisted of assessing 
concurrent psychotropic medications, significant nasal pathology, as well as measuring 
vitals (e.g., blood pressure, pulse). Participants were then asked to complete a set of self-
report questionnaires to collect demographic information, as well as to assess baseline 
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levels of depression using the Beck Depression Inventory- II (Beck, Steer, & Brown, 
1996), social anxiety using the Social Interaction and Anxiety Scale (Mattick & Clarke, 
1998), rejection sensitivity using the Interpersonal Sensitivity Measure (Boyce & Parker, 
1989; Harb, Heimberg, Fresco, Schneier, & Liebowitz, 2002), subjective mood using the 
Positive and Negative Affect Scales (Watson, Clark, & Tellegen, 1988), and attachment 
orientation using the Experience in Close Relationships Inventory (ECR) (Brennan, 
Clark, & Shaver, 1998). The ECR is a 36-item self-report questionnaire that yields two 
subscales reflecting attachment anxiety (anxiety about being rejected or abandoned) and 
attachment avoidance (discomfort with closeness and intimacy). In the current study, the 
two subscales were not significantly correlated, r = -.32, n = 25, p = .12.   
Next, participants were randomly assigned to receive a nasal spray containing 
either oxytocin or placebo using a computer-generated pre-randomization sheet. The 
study was double-blind, such that neither the study physician nor the experimenter were 
aware of participants’ assigned drug condition. Using a standardized protocol, 
participants self-administered a metered-dose nasal spray with three puffs per nostril (4 
IU of oxytocin or placebo per puff) in the presence of the study physician or nurse. After 
nasal spray administration, participants’ vitals were measured again.  
Participants were then asked to sit in an isolated waiting room for 45 minutes 
before starting the computer tasks, as this reflects a standard wait period following 
intranasal oxytocin administration. After 45 minutes, participants were led to a common 
waiting area for the study, where they were told that they would have an opportunity to 
briefly meet three other study participants for the first task. The experimenter led the 
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participant and three male confederates individually into the waiting area, and asked each 
participant to introduce their first name to the group. At this time, participants were 
individually led to their separate experimental rooms.  
Participants played Cyberball first, and then completed the post-Cyberball 
questionnaires. Afterwards, participants completed the modified Posner Task. The 
experiment concluded with a debriefing session.  
 
Statistical Analyses 
Primary Analyses. First, a series of mixed between-within analyses of variance 
(ANOVAs) were conducted to examine group effects on social outcomes during 
Cyberball, and attentional outcomes during the Posner Task. Specifically, Cyberball 
outcomes included: 1) number of balls thrown to Player 1 during the Play and Switch 
conditions, 2 (Group: oxytocin, placebo) x 2 (Time: balls tossed to Player 1 during Play 
and Switch conditions), 2) the number of balls thrown to each of the other players during 
the Play condition, 2 (Group: oxytocin, placebo) x 3 (Player: balls tossed to Player 1, 3, 
and 4), and 3) overall trust and rejection ratings for each of the players, 2 (Group: 
oxytocin, placebo) x 3 Player (trust and rejection ratings for Player 1, 3, and 4). On the 
Posner Task, faster response latencies when detecting validly cued targets following 
disgust faces indicated an attentional “engagement” or bias toward threat-relevant 
information. Slower response latencies when detecting invalidly cued targets following 
disgust faces indicated difficulty disengaging attention away from threat-relevant 
information. To examine the effect of oxytocin on attentional engagement and 
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disengagement by face type, a mixed 2 (Group: oxytocin, placebo) x 2 (Cue Type: valid, 
invalid) x 3 (Face Type: disgust, neutral, happy) ANOVA was conducted with repeated 
measurement on the last two factors. To examine group differences on demographic 
characteristics and baseline clinical measures, t-tests were conducted for continuous 
variables and chi-square tests were conducted for categorical variables. Given that there 
were no significant differences in age and social anxiety symptom severity between 
groups, and that inclusion of covariates would significantly reduce test power, we did not 
control for covariates in the analyses. Thus, covariates were not included in the reported 
analyses moving forward.  
Secondary Analyses. A regression approach was adopted to investigate the 
interactions between drug and continuous moderators (rejection sensitivity, attachment 
anxiety, and attachment avoidance) on Cyberball outcomes (ball-tossing behavior, ratings 
of trust and rejection), as well as outcomes during the Posner Task (attentional 
engagement and disengagement scores for each face type). We conducted hierarchical 
regression analyses on all participants in the sample to examine the effects of drug group 
(dummy coded: 1 = oxytocin and 0 = placebo), and mean-centered rejection sensitivity 
(entered in step 1), and their two-way interaction (entered as a product term in step 2), on 
each outcome. The regressions were then repeated to examine the effects of drug group 
(dummy coded: 1 = oxytocin and 0 = placebo), and mean-centered attachment anxiety 
and attachment avoidance (entered in step 1), and their two- and three-way interactions 
(entered as product terms in steps 2 and 3, respectively) on the same outcomes. 
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Regression analyses were followed up by generating predicted values based on each 
regression equation and plotting XY graphs to examine the nature of the interaction.  
 
Results 
Primary Analyses 
Effect on cooperation. Oxytocin, relative to placebo, did not lead to continued 
cooperation with Player 1 across the two conditions during the game, as there was no 
significant Group x Time interaction, Wilks’ Lambda = 1.00, F(1,50) = .02, p = .88, ηp
2
 = 
.00. Both groups showed a reduction in ball tosses to Player 1 during the game, Wilks’ 
Lambda = .66, F(1,50) = 26.37, p < .001, ηp
2 
= .34, but this did not differ by group, 
F(1,50) = .70, p = .41, ηp
2 
= .01. In addition, oxytocin, relative to placebo, was not 
significantly associated with more throws to Player 1, compared to other players, as there 
was no significant Group x Player interaction, Wilks’ Lambda = .99, F(2, 49) = .24, p = 
.78, ηp
2 
= .01. Both groups threw significantly more balls to Player 1 compared to other 
players, Wilks’ Lambda = .47, F(2,49) = 27.32, p < .001, ηp
2 
= .53, but this did not differ 
by group, F(1,50) = .32, p = .57, ηp
2 
= .01.  
Effect on perceived trust and rejection. Oxytocin, relative to placebo, did not 
significantly impact trust ratings for Player 1 compared to other players, Wilks’ Lambda 
= .98, F(2,47) = .44, p = .64, ηp
2 
= .02, nor did oxytocin significantly impact perceived 
rejection ratings from Player 1, Wilks’ Lambda = .99, F(2,47) = .27, p = .77, ηp
2 
= .01. 
However, those who received oxytocin reported lower ratings of overall rejection from 
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all players during Cyberball, relative to those who received placebo, F(1,48) = 3.98, p = 
.05, ηp
2 
= .08.  
Effect on attentional engagement and disengagement of social cues. First, 
response times for inaccurate trials were eliminated. Inaccurate trials consisted of trials 
where the probe was the letter “E” and the participant pressed the right mouse button or 
vice versa. This resulted in elimination of 2% of the trials. Response latencies less than 
360 ms and greater than 2200 ms were considered outliers and eliminated from the 
analysis. Idiographic standardization of response times was then conducted, and response 
latencies from trials reflecting two standard deviations above or below an individual’s 
personal mean were eliminated from the analysis, which resulted in elimination of 4% of 
the trials. Finally, for each participant, a mean response time was calculated for each face 
type and cue condition.  
Oxytocin was not associated with facilitated attentional engagement or 
disengagement scores for any emotional face type, as there was no significant interaction 
of Group x Cue Type x Face Type, Wilks’ Lambda = .93, F(2,50) = .44, p = .65. We then 
conducted separate Group x Cue Type analyses for each face type, and found no 
significant interactions: disgust faces, Wilks’ Lambda = 1.00, F(1,51) = .15, p = .70; 
happy faces, Wilks’ Lambda = 1.00, F(1,51) = .09, p = .77; and, neutral faces, Wilks’ 
Lambda = .99, F(1,51) = .70, p = .41. There were no other significant main effects.  
Cyberball manipulation check. Nine (17.3%) out of 52 participants who 
completed Cyberball reported that they did not notice a change in any player’s behavior 
during the game. However, of those who did notice a change, participants reported that 
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Player 1 played the most with them at first, Wilks’ Lambda = .66, F(2,44) = 11.15, p < 
.001, ηp
2 = .34, and that there was no significant difference between the other players’ 
behavior later on during the Switch condition of the game, Wilks’ Lambda = .95, F(2,44) 
= 1.28, p = .29, ηp
2 
= .06.  
 
Secondary Analyses 
Effect on cooperation. Regression analyses revealed a significant Group x 
Attachment Avoidance interaction on difference scores in balls tossed to Player 1 during 
Cyberball, B = 6.90, t(19) = 2.11, p = .05. The attachment interaction terms contributed to 
the overall model by explaining an additional 19.9% of the variance in ball tosses, F 
change (2,19) = 2.72, p = .09. Among participants with low Attachment Avoidance, 
oxytocin resulted in smaller difference scores in the number of balls tossed to Player 1 
between the Play and Switch conditions compared to placebo, which suggested greater 
cooperation with Player 1. Among participants with high Attachment Avoidance, 
oxytocin resulted in greater difference scores across the Cyberball conditions compared 
to placebo, which suggested decreased cooperation with Player 1. There was no 
significant Group x Attachment Anxiety interaction on difference scores in balls tossed to 
Player 1, B = -.91, t(19) = -.32, p = .75, as well as no significant Group x Rejection 
Sensitivity interaction on difference scores in balls tossed to Player 1, B = .30, t(42) = 
1.23, p = .23.  
Effect on perceived trust and rejection. Regression analyses showed a significant 
Group x Rejection Sensitivity interaction on overall ratings of perceived rejection from 
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other players during Cyberball, B = .07, t(42) = 2.44, p = .02. The interaction effect 
explained a significant portion of variance in rejection ratings, R
2
 change = .12, F change 
(1,42) = 5.97, p = .02. Among participants with high Rejection Sensitivity, oxytocin 
resulted in greater overall perceived rejection from the other players compared to 
placebo. In contrast, among those with low Rejection Sensitivity, oxytocin resulted in 
lower levels of overall perceived rejection compared to placebo. There was no significant 
Group x Rejection Sensitivity interaction on trust, B = -.01, t(42) = -.16, p = .87. There 
was also no significant Group x Attachment Anxiety interaction on trust, B = -.004, t(19) 
= -.02, p = .99, or rejection, B = .37, t(19) = .84, p = .41, and no significant Group x 
Attachment Avoidance interaction on trust, B = .08, t(19) = .26, p = .80, or rejection, B = 
.41, t(19) = .82, p = .42.  
Effect on attentional engagement and disengagement of social cues. Regression 
analyses showed a significant Group x Attachment Avoidance interaction on engagement 
scores for disgust faces, B = -106.12, t(18) = -2.34, p = .03, and neutral faces, B = -
102.47, t(18) = -2.07, p = .05, but not for happy faces, B = -81.30, t(18) = -1.52, p = .15. 
When given oxytocin, individuals with high Attachment Avoidance responded faster to 
validly cued disgust faces and neutral faces, whereas individuals with low Attachment 
Avoidance took longer to respond. For disengagement scores, there was a trend toward a 
group difference for the Group x Attachment Avoidance interaction for all face types: 
disgust faces, B = -106.87, t(19) = -1.98, p = .06; neutral faces, B = -99.14, t(19) = -1.82, 
p = .09; and, happy faces, B = -93.32, t(19) = -2.03, p = .06. When given oxytocin, 
individuals with high Attachment Avoidance responded faster to invalidly cued disgust, 
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neutral, and happy faces, whereas individuals with low Attachment Avoidance took 
longer to respond. Although the product terms explained an additional portion of variance 
in engagement and disengagement scores, none of the changes in R
2
 were significant, all 
p’s > .05. There was no significant Group x Attachment Anxiety interaction on 
engagement scores for any face type (all p’s > .05). There was also no significant Group 
x Attachment Anxiety interaction on disengagement scores for any face type (all p’s > 
.05).  
Furthermore, although regression analyses showed no significant interactions 
between Group x Rejection Sensitivity on engagement and disengagement scores for 
each face type, there was a significant effect of Rejection Sensitivity on disengagement 
from happy faces, B = 4.69, t(47) = 2.00, p = .05, suggesting that greater rejection 
sensitivity was associated with longer response latencies for invalid trials involving 
happy faces. 
 
Self-Reported Mood and Social Interaction Anxiety  
Oxytocin did not significantly reduce self-reported negative mood, positive mood, 
or social interaction anxiety, as all of these interaction effects were non-significant 
(negative mood: Wilks’ Lambda = 1.00, F(1,50) = .23, p = .63, ηp
2 
= .01; positive mood: 
Wilks’ Lambda = .99, F(1,51) = .57, p = .45, ηp
2 
= .01; social interaction anxiety: Wilks’ 
Lambda = 1.00, F(1,23) = .01, p = .91, ηp
2 
= .001). Interestingly, both groups showed 
improved positive mood during Cyberball, Wilks’ Lambda = .84, F(1,51) = 9.61, p = 
.003, ηp
2 
= .16, but this did not differ by group, F(1,51) = .74, p = .39, ηp
2 
= .01.  
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Discussion 
Previous literature on the effect of oxytocin in clinical samples shows mixed 
findings, as some studies demonstrate contrasting effects of oxytocin, even within the 
same disorder (Dadds et al., 2013; Tachibana et al., 2013). The current study sought to 
investigate the context-dependent effects of oxytocin under conditions of cooperation and 
rejection by relatively anonymous others, and the possible attentional mechanisms that 
may underlie oxytocin’s pro-social effects, among individuals with SAD.  
 The current findings show that oxytocin contributed to ongoing cooperative play 
with a rejecting but initially cooperative other (Player 1) for individuals with low 
attachment avoidance. In addition, we showed that oxytocin amplified subjective ratings 
of perceived rejection by others during Cyberball for those with high rejection sensitivity, 
and appeared to only buffer responses to rejection for those with already low rejection 
sensitivity. Finally, results suggest that for those with high attachment avoidance, 
oxytocin not only facilitated disengagement from all social cues depicting disgust, 
neutral, and happy faces, but also speeded up the detection of disgust and neutral faces in 
particular.  
These findings join a body of literature showing that oxytocin’s effects are highly 
dependent on individual differences, such as attachment orientation (Bartz et al., 2011), 
and that oxytocin may only benefit individuals who stand to gain in terms of 
socioemotional functioning (Olff et al., 2013). It may be possible that oxytocin increased 
the salience of Player 1’s alliance-forming behavior early on in the game, particularly for 
individuals with low attachment avoidance, which facilitated the social categorization of 
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Player 1 as an in-group member (De Dreu, 2012a; Van Ijzendoorn & Bakermans-
Kranenburg, 2012). It is also possible that oxytocin led to ongoing cooperation with 
Player 1 through reduced betrayal aversion, as this has been shown in previous research 
to be true only for individuals with high attachment avoidance (De Dreu, 2012b). 
Interestingly, oxytocin did not universally benefit a group of severely symptomatic, 
highly rejection sensitive SAD patients, given that only those with low baseline levels of 
rejection sensitivity and attachment avoidance showed improved social outcomes after 
receiving oxytocin, relative to placebo. The sample mean on the IPSM was 82.91, which 
is comparable to reported norms in SAD samples on this measure (Harb et al., 2001). 
This may be consistent with the notion that oxytocin may have strongest effects for those 
within a moderate range of abnormal functioning, but may have no benefits beyond that 
range (Guastella et al., 2010).  
Consistent with previous studies, our findings also suggest that oxytocin 
facilitates a flexible attentional pattern in individuals with SAD, such that it may promote 
an existing attentional bias toward social threat cues, but also enable faster 
disengagement from them (Domes et al., 2013; Ellenbogen et al., 2012; Guastella et al., 
2008). In this way, oxytocin may enhance the very mechanisms targeted in attention 
retraining interventions for SAD (Amir et al., 2009).  
The primary limitation of this study is the lack of a healthy control group, which 
restricts conclusions about the comparative effects of oxytocin. In addition, these findings 
may not generalize to females, children, or older adults, especially in light of sex and age 
effects on oxytocin. Future studies should replicate the study across these groups. 
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Notwithstanding, our study represents one of the earliest studies examining oxytocin in 
SAD, and extends previous work highlighting oxytocin’s potential to inform the 
pathophysiology and treatment of SAD.    
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Table 1. Demographic Characteristics by Group 
 
 Mean (SD) Statistic 
 OT 
(n = 27) 
PBO 
(n = 27) 
Value
a,b
 p-value 
Age
b
 (years) 24.70 (7.14) 24.07 (5.96) 0.35 .73 
Ethnicity (%, n) 
     Hispanic or Latino 
     Non-Hispanic or Latino 
 
14.81 (4) 
85.19 (23) 
 
11.11 (3) 
88.89 (24) 
0.16 .69 
Race
a
 (%, n)  
     White 
     Black or African American 
     Asian 
     Other 
 
70.37 (19) 
7.41 (2) 
14.81 (4) 
7.41 (2) 
 
59.26 (16) 
11.11 (3) 
35.93 (7) 
3.70 (1) 
1.61 .66 
Marital status
a
 (%, n) 
     Single 
     Living with partner 
     Married 
     Divorced 
 
85.19 (23) 
3.70 (1) 
7.41 (2) 
3.70 (1) 
 
88.89 (24) 
11.11 (3) 
0.00 (0) 
0.00 (0) 
4.02 .26 
Education
a
 (%, n) 
     Graduate School 
     College Graduate 
     Partial College 
     High School Graduate 
 
7.41 (2) 
37.04 (10) 
51.85 (14) 
3.70 (1) 
 
29.63 (8) 
22.22 (6) 
37.04 (10) 
11.11 (3) 
6.27 .10 
Occupational status
a 
(%, n)  
     Not applicable 
     Full-time employment 
     Part-time employment 
     Dependent on spouse or is    
a student 
 
35.93 (7) 
18.52 (5) 
22.22 (6) 
33.33 (9) 
 
14.81 (4) 
18.52 (5) 
35.93 (7) 
40.74 (11) 
1.10 .78 
Age of onset of SAD
b
 14.70 (6.00) 14.19 (5.02) 0.34 .73 
LSAS
b
  82.30 (17.87) 82.48 (16.30) -0.04 .97 
SIAS
b
 50.40 (10.35) 47.54 (11.89) 0.84 .37 
BDI-II
b
 15.08 (7.59) 15.30 (8.80) -0.10 .92 
IPSM
b
 83.74 (6.56) 81.88 (9.27) 0.63 .43 
ECR: Avoidance
b
 3.43 (0.89) 3.61 (0.98) 0.24 .63 
ECR: Anxiety
b
 4.47 (1.02) 3.90 (1.13) 1.78 .20 
Note. OT = Oxytocin; PBO = Placebo; SAD = Social Anxiety Disorder; LSAS = 
Liebowitz Social Anxiety Scale; SIAS = Social Interaction Anxiety Scale; BDI-II = Beck 
Depression Inventory; IPSM = Interpersonal Sensitivity Measure; ECR = Experience in 
Close Relationships Inventory 
a
Chi-square statistics reported for selected variables 
b
t-values reported for all clinical measures and age  
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Table 2. Summary of Hierarchical Regression Analysis for Effect of Group and Attachment Orientation on Ball-Tossing 
Behavior (n = 25) 
 
 Model 1 Model 2 Model 3 
Variable B SE B ß B SE B ß B SE B ß 
Group 1.69 3.12 .12 1.71 2.89 .12 2.29 3.06 .16 
Attachment Avoidance 1.53 1.76 .19 -1.72 2.24 -.21 -1.72 2.27 -.21 
Attachment Anxiety -1.51 1.53 .22 -1.04 1.95 -.15 -1.04 1.98 -.15 
Group x Attachment Avoidance    6.90 3.28 .58* 7.13 3.34 .60* 
Group x Attachment Anxiety    -.91 2.84 -.09 -1.03 2.89 -.10 
Group x Attachment Avoidance 
x Attachment Anxiety 
      1.81 2.67 .14 
R
2
 .11   .31   .32   
F for change in R
2
 .83   2.72   .46   
Note. Group dummy coded (OT = 1, PBO = 0). Attachment Avoidance and Attachment Anxiety centered at their means.  
* p < .05.  
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Table 3. Summary of Hierarchical Regression Analysis for Effect of Group and Rejection 
Sensitivity on Overall Ratings of Perceived Rejection (n = 46) 
 
 Model 1 Model 2 
Variable B SE B ß B SE B ß 
Group -.31 .22 -.22 -.34 .21 -.24 
Rejection Sensitivity -.004 .01 -.05 -.03 .02 -.29 
Group x Rejection 
Sensitivity 
   .07 .03 .42* 
R
2
 .05   .17   
F for change in R
2
 1.16   5.97*   
Note. Group dummy coded (OT = 1, PBO = 0). Rejection Sensitivity centered at its mean.  
* p < .05.  
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Table 4. Mean Response Latency (ms) by Cue Type and Face Type for Each Group 
 
 Oxytocin Placebo 
Face type Mean (SD) Mean (SD) 
Disgust   
     Valid 603.13 (94.51) 646.08 (89.74) 
     Invalid 601.44 (101.20) 638.26 (108.98) 
Neutral   
     Valid 607.77 (95.68) 655.12 (104.71) 
     Invalid 600.10 (95.92) 635.54 (93.13) 
Happy   
     Valid 610.22 (107.27) 642.71 (92.22) 
     Invalid 598.84 (88.99) 635.53 (110.80) 
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Figure 1. Number of Ball Tosses Across Cyberball Conditions by Group
a,b 
 
  
 
 
a 
Error bars indicate standard error of the mean. 
* p < .001. 
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Figure 2. Significant Interaction Effect of Group x Attachment Avoidance on Difference 
Scores in Ball Tosses to Player 1 between Play and Switch Conditions (n = 25) 
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Figure 3. Significant Interaction Effect of Group x Rejection Sensitivity on Overall 
Ratings of Perceived Rejection (n = 46) 
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Figure 4. Significant Interaction Effect of Group x Attachment Anxiety on Attentional 
Engagement Toward Disgust Faces (n = 24) 
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